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These clinical guidelines have been developed to assist in the
management of patients presenting with chest pain sus-
pected to be due to an acute coronary syndrome (ACS)
and those with confirmed ACS. These guidelines should
be read in conjunction with the ACS Clinical Care Standardsdeveloped by the Australian Commission for Safety and
Quality in Health Care (ACSQHC) [1] and the Australian
acute coronary syndromes capability framework developed by
the Heart Foundation [2]. Additional guidance around the
timing and use of therapies is detailed in the accompanying
practice advice.
Key Evidence-Based Recommendations
Recommendation GRADE strength of
recommendation
NHMRC Level of
Evidence (LOE)
Initial assessment of chest pain
It is recommended that a patient with acute chest pain or
other symptoms suggestive of an ACS receives a 12-lead ECG
and this ECG is assessed for signs of myocardial ischaemia by
an ECG-experienced clinician within 10 minutes of first acute
clinical contact.
Strong IIIC
A patient presenting with acute chest pain or other
symptoms suggestive of an ACS should receive care guided
by an evidence-based Suspected ACS Assessment Protocol
(Suspected ACS-AP) that includes formal risk stratification.
Strong IA
Using serial sampling, cardiac-specific troponin levels
should be measured at hospital presentation and at clearly
defined periods after presentation using a validated Suspected
ACS-AP in patients with symptoms of possible ACS.
Strong IA
Non-invasive objective testing is recommended in
intermediate-risk patients, as defined by a validated Suspected
ACS-AP, with normal serial troponin and ECG testing and
who remain symptom-free.
Weak IA
Patients in whom no further objective testing for coronary
artery disease (CAD) is recommended are those at low risk, as
defined by a validated Suspected ACS-AP: age <40 years,
symptoms atypical for angina, in the absence of known CAD,
with normal troponin and ECG testing, and who remain
symptom-free.
Weak III-3C
Diagnostic considerations and risk stratification of ACS
The routine use of validated risk stratification tools for
ischaemic and bleeding events (e.g. GRACE score for
ischaemic risk or CRUSADE score for bleeding risk) may
assist in patient-centric clinical decision-making in regards to
ACS care.
Weak IIIB
Acute reperfusion and invasive management strategies in ACS
For patients with ST elevation myocardial infarction
(STEMI) presenting within 12 hours of symptom onset, and in
the absence of advanced age, frailty and comorbidities that
influence the individual’s overall survival, emergency
reperfusion therapy with either primary percutaneous
coronary intervention (PCI) or fibrinolytic therapy is
recommended.
Strong IA
Primary PCI is preferred for reperfusion therapy in
patients with STEMI if it can be performed within 90 minutes
of first medical contact; otherwise fibrinolytic therapy is
preferred for those without contra-indications.
Strong IA
Among patients treated with fibrinolytic therapy who are
not in a PCI-capable hospital, early or immediate transfer to a
PCI-capable hospital for angiography, and PCI if indicated,
within 24 hours is recommended.
Weak IIA
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Recommendation GRADE strength of
recommendation
NHMRC Level of
Evidence (LOE)
Among patients treated with fibrinolytic therapy, for those
with 50% ST recovery at 60–90 minutes, and/or with
haemodynamic instability, immediate transfer for angiography
with a view to rescue angioplasty is recommended.
Strong IB
Among high- and very high-risk patients with non-ST
elevation acute coronary syndromes (NSTEACS) (except Type
2 MI), a strategy of angiography with coronary
revascularisation (PCI or coronary artery bypass grafts) where
appropriate is recommended.
Strong IA
Patients with NSTEACS who have no recurrent symptoms
and no risk criteria are considered at low risk of ischaemic
events, and can be managed with a selective invasive strategy
guided by provocative testing for inducible ischaemia.
Strong IA
Timing of invasive management for NSTEACS
Very high-risk patients: Among patients with NSTEACS
with very high-risk criteria (ongoing ischaemia,
haemodynamic compromise, arrhythmias, mechanical
complications of MI, acute heart failure, recurrent dynamic or
widespread ST-segment and/or T-wave changes on ECG), an
immediate invasive strategy is recommended (i.e. within 2
hours of admission).
Strong IIC
High-risk patients: In the absence of very high-risk criteria,
for patients with NSTEACS with high-risk criteria (GRACE
score >140, dynamic ST-segment and/or
T-wave changes on ECG, or rise and/or fall in troponin
compatible with MI) an early invasive strategy is
recommended (i.e. within 24 hours of admission).
Weak IC
Intermediate risk patients: In the absence of high-risk
criteria, for patients with NSTEACS with intermediate-risk
criteria (such as recurrent symptoms or substantial inducible
ischaemia on provocative testing), an invasive strategy is
recommended (i.e. within 72 hours of admission).
Weak IIC
Pharmacology for ACS
Aspirin 300 mg orally initially (dissolved or chewed)
followed by 100–150 mg/day is recommended for all patients
with ACS in the absence of hypersensitivity.
Strong IA
Among patients with confirmed ACS at intermediate to
very high- risk of recurrent ischaemic events, use of a P2Y12
inhibitor (ticagrelor 180 mg orally, then 90 mg twice a day or;
prasugrel 60 mg orally, then 10 mg daily; or clopidogrel
300–600 mg orally, then 75mg per day) is recommended in
addition to aspirin. (Ticagrelor or prasugrel preferred: see
practice advice)
Strong IA
Intravenous glycoprotein IIb/IIIa inhibition in combination
with heparin is recommended at the time of PCI among
patients with high-risk clinical and angiographic
characteristics, or for treating thrombotic complications
among patients with ACS.
Strong IB
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Recommendation GRADE strength of
recommendation
NHMRC Level of
Evidence (LOE)
Either unfractionated heparin or enoxaparin is
recommended in patients with ACS at intermediate to high
risk of ischaemic events.
Strong IA
Bivalirudin (0.75 mg/kg IV with 1.75 mg/kg/hr infusion)
may be considered as an alternative to glycoprotein IIb/IIIa
inhibition and heparin among patients with ACS undergoing
PCI with clinical features associated with an increased risk of
bleeding events.
Weak IIB
Discharge management and secondary prevention
Aspirin (100–150 mg/day) should be continued indefinitely
unless it is not tolerated or an indication for anticoagulation
becomes apparent.
Strong IA
Clopidogrel should be prescribed if aspirin is
contraindicated or not tolerated.
Strong IA
Dual-antiplatelet therapy with aspirin and a P2Y12
inhibitor (clopidogrel or ticagrelor) should be prescribed for
up to 12 months in patients with ACS, regardless of whether
coronary revascularisation was performed. The use of
prasugrel for up to 12 months should be confined to patients
receiving PCI.
Strong IA
Consider continuation of dual-antiplatelet therapy beyond
12 months if ischaemic risks outweigh the bleeding risk of
P2Y12 inhibitor therapy; conversely consider discontinuation if
bleeding risk outweighs ischaemic risks.
Weak IIC
Initiate and continue indefinitely, the highest tolerated
dose of HMG-CoA reductase inhibitors (statins) for a patient
following hospitalisation with ACS unless contraindicated or
there is a history of intolerance.
Strong IA
Initiate treatment with vasodilatory beta blockers in
patients with reduced left ventricular (LV) systolic function
(LV ejection fraction [EF] 40%) unless contraindicated.
Strong IIA
Initiate and continue angiotensin converting enzyme (ACE)
inhibitors (or angiotensin receptor blockers [ARBs]) in patients
with evidence of heart failure, LV systolic dysfunction,
diabetes, anterior myocardial infarction or co-existent
hypertension.
Strong IA
Attendance at cardiac rehabilitation or undertaking a
structured secondary prevention service is recommended for
all patients hospitalised with ACS.
Strong IA
Note: Refer to Appendix 4 for details on the National Health and Medical Research Council (NHMRC) guideline development methodology, including grades of
evidence, and Appendix 5 for details on the GRADE methodology.
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1.1. Incidence
Acute coronary syndromes (ACS) – myocardial infarction
(MI) and unstable angina (UA) – are the result of unstable
atheromatous plaques or endothelial disruption with asso-
ciated transient or permanent thrombotic occlusion of the
coronary vascular tree leading to myocardial ischaemia
and infarction. As a result of the improved sensitivity of
troponin assays, incidence of unstable angina is decreasing
with a proportionate increase in the incidence of MI. In
2012, the Australian Institute of Health and Welfare esti-
mated there were 68,200 ACS events [3]. Chest pain and
other symptoms suggestive of possible ACS are common
presenting complaints in the emergency department (ED)
[4]. It is estimated that over 500,000 patients present in
Australia each year with chest pain, but more than 80% of
all patients investigated for ACS will not have this diag-
nosis confirmed [5]. In unselected patients presenting with
acute chest pain to the ED in the Australian setting, the
prevalence of different diagnostic groups are: 2-5% ST
elevation MI (STEMI), 5-10% Non-STEMI (NSTEMI), 5-
10% UA, 15-20% other cardiac conditions and 50-70%
non-cardiac diseases [5–7]. The costs and burden of the
diagnostic process to patients, clinicians and the healthcare
system are significant.
1.2. Contemporary Outcomes of ACS
and Chest Pain in Australia
Patient level estimates of overall 30-day outcomes and 12-
month mortality rates within Australian contemporary prac-
tice, as ascertained by recent clinical audits, are provided as a
reference for estimating the absolute benefits for variousTable 1 Kaplan-Meier event rates for ACS diagnosis adjuste
STEMI N
Death or MI by 30 days 12.7% 6
In hospital major bleeding 2.4% 1
Death by 12 months 9.8% 6
Death or MI by 12 months 17.7% 15
Death/MI/stroke by 12 months 18.6% 16
Table 2 Relative increase in ischaemic and bleeding events w
Relative increase i
MACE OR (9
Age >75 years vs age 75 years 1.69 (1.15–
Female gender vs male gender 1.19 (0.83–
Diabetes vs non-diabetes 1.53 (1.05–
CKD Stage 3-5 vs CKD Stage 1-2 2.81 (1.96–
CKD=chronic kidney disease; CI=confidence interval; OR=odds ratio; MACE=Majoguideline recommended therapies and strategies (Table 1)
in the ‘average’ patient. In deriving estimates of the absolute
reduction or increase in events as a result of specific treat-
ments, the relative effects for each treatment seen in trials is
applied to the estimated baseline absolute event rates seen in
audits. This absolute change in events is then used to calcu-
late the number needed to treat to benefit (NNTB) (e.g.
reducing recurrent MI) and the number needed to treat to
harm (NNTH) (e.g. treatment-related bleeding or adverse
events). These figures should be considered an approxima-
tion as clinical audits comprise patients who have received
varying intensities of different interventions, as opposed to
clinical trials where, apart from the specific intervention
under study, all other forms of care are provided equally.
When considering the use of evidence-based recommenda-
tions in individual patients, patient-specific disease and
treatment risks, and therefore potential benefits and harms
from therapies, should be weighed. The relative increase in
both risks associated with key clinical and demographic
characteristics within the Australian and New Zealand clini-
cal experience is provided in Table 2.
1.3. The Process of Developing the 2016
ACS Guidelines
This clinical guideline for the management of ACS seeks to
provide guidance regarding the clinical care of patients pre-
senting with suspected or confirmed ACS. It is intended to
replace the National Heart Foundation of Australia (NHFA)/
Cardiac Society of Australia and New Zealand (CSANZ)
ACS guideline published in 2006, 2008 and 2011[8–10].
The methodology used in the development of this guideline
was guided by the methodological expertise of working
group members [11].d for age from SNAPSHOT ACS
STEMI Unstable angina Chest pain
.8% 1.2% 0.7%
.4% 1.0% 0.2%
.0% 1.7% 2.9%
.1% 5.1% 4.9%
.2% 7.0% 5.9%
ith key clinical characteristics from SNAPSHOT ACS
n in-hospital
5% CI)
Relative increase in in-hospital
bleeding events OR (95% CI)
2.45) 1.36 (0.58–3.00)
1.72) 0.91 (0.40–1.97)
2.21) 1.60 (0.73–3.40)
4.04) 1.91 (0.89–4.03)
r adverse cardiac events
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 In mid-2014, officers of the NHFA and a small group of
senior cardiologists representing the CSANZ, together
with a methodologist, formed an ad hoc group to initiate
the process of developing the 2016 guideline.
 This group approached the Cardiac Clinical Networks
around Australia seeking feedback regarding the content
and development process for the guideline.
 In December 2014, the ad hoc group, under a formal
partnership between NHFA and CSANZ, and acting on
advice from the previous expert panel responsible for prior
editions of the guideline, sought representation from key
stakeholder organisations for experts in ACS management
to contribute to the process of guideline development.
 Among those canvassed as recognised clinical experts in
chest pain and ACS management, proposed contributors
where offered roles in either a reference group, which had
the role of critical review of the entire guideline content, or
work groups focussing on guideline writing related to
specific topics.Reference group
 This group comprised nominated representatives of iden-
tified key stakeholder organisations with national rele-
vance in the provision of ACS care in Australia.
 The roles of the group were to review and provide input
into the scope of the guidelines, the questions being sub-
mitted for literature review, draft guideline content and
recommendations, and issues of implementation.Guideline work groups
 Work groups were established for each of four topics: chest
pain assessment, STEMI, non-ST segment elevation ACS
(NSTEACS) and secondary prevention. For each work
group, among all those who agreed to join the group, a
primary author and senior advisor were appointed by
group consensus on the basis of expertise and previous
experience in guideline development.
 Each work group was then supplemented with members
with recognised expertise from stakeholder groups and the
clinical community.
 Members of each work group met on several occasions to
discuss the content of each of the four sections of the
guideline.Executive group
 The primary author and senior advisor from each of the
four workgroups and representatives from the NHFA
formed an executive group with overall responsibility
for the progression, content and consistency of the guide-
line, and for resolving disputes within or between work
groups relating to guideline content and recommendations
or conflicts of interest. The executive group had several meetings throughout
2015 and 2016, to discuss and refine the full content of
the draft guidelines, with particular focus on the wording
and grading of final recommendations.
 The executive group had the authority for final approval of
guideline content and recommendations.Literature reviews
 Informed by stakeholder consultation, each of the work
groups proposed sentinel questions, presented in PICO
format (population, intervention, comparator and out-
come), for external literature review. These questions were
reviewed and refined by the reference group. The ques-
tions proposed for literature review are provided in the
appendix.
 The literature reviewer was appointed through an open
tender process. The literature review sought published
studies from 2010 to 2015. The process of literature review
was commenced in the second quarter of 2015 and com-
pleted in the fourth quarter of 2015. Evidence summaries
were reviewed and signed off by the work groups and,
where deemed appropriate, were supplemented with
additional studies published after the literature search
dates.Finalisation phase
 In December 2015, the full first draft of the guideline was
given to members of the reference group for detailed com-
ments. These comments were received and responses
drafted in February 2016.
 A public consultation period of 30 days was conducted in
April 2016.
 Final approval and submission for publication was under-
taken in June 2016.
1.4. Conflicts of Interest Process
Conflicts of interest were considered within a framework of
both the relationship (direct or indirect) of the participating
individual to any third party with interest in the topic under
consideration within the guideline development process, and
the nature (financial and non-financial) of the potential con-
flict. All members of the work groups and reference group
were asked to declare all potential conflicts of interest and
these declarations were updated every six months and at
each meeting. Individuals with pecuniary or academic con-
flicts of interest deemed to be high were excluded from the
drafting of specific recommendations. All other conflicts of
interest were managed by the work group chair or senior
advisor, under guidance from the executive group. The exec-
utive group was responsible for managing conflicts of inter-
est. A summary of the conflicts of interest and executive
group responses is provided in the online appendix and a
full description of the governance process for the develop-
ment of this guideline will be available on the NHFA website.
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In developing this document, we sought to provide practical
guidance for contemporary ACS care in Australia derived
from the extensive evidence base regarding the clinical effec-
tiveness of different interventions and treatment strategies.
In addition to reviews of published trials and systematic
reviews, guideline content was informed by other interna-
tional clinical guidelines, the Acute Coronary Syndrome Clini-
cal Care Standard and local clinical expertise. In formulating
recommendations, we focussed on clinical actions likely to be
associated with the largest impact on patient-important out-
comes. The guidelines are presented in the format described
below.
The key ‘Recommendations’ are presented up-front for
easy identification. In making these recommendations, we
chose to provide a strength of recommendation (strong or
weak) according to the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) system
(12) (Refer to Appendix 5) alongside the National Health and
Medical Research Council (NHMRC) level of evidence
scheme [13] (Refer to Appendix 4). The executive group
considered that providing a clear dichotomous statement
regarding the strength of the recommendation – strong
versus weak - would benefit clinicians seeking to prioritise
use of interventions in clinical practice, develop systems
designed to provide more consistent care, or formulate qual-
ity indicators for reviewing clinical performance. Each of the
final recommendations was independently reviewed and
refined by the work groups and the reference group, with
final review and endorsement by the executive group. The
definition of consensus was >80% agreement of all members
of the executive group.
The ‘Rationale’ section provides a very brief summary of
the key evidence. In this section, treatment effects are pre-
sented in relative terms, i.e. odds ratios [OR], risk ratios [RR]
or hazard ratios [HR] (with 95% confidence intervals). Hence
an OR of 0.90 represents a 10% relative reduction in the event.
We have confined the reporting of treatment effects to those
that were significant to a p-value of <0.05, with the exception
of mortality outcomes where relevant to the weighing of the
evidence.
To assist in the translation of these treatment effects into
clinical decision-making, we have attempted to provide,
wherever possible, estimates of the absolute changes inintervention-specific outcomes such as ischaemic episodes
or care-related adverse events for the ‘average’ patient, in the
section ‘Benefits and harms’. This approach has been used to
assist clinicians in their discussions with patients by quanti-
fying the likely absolute benefits or risks associated with each
guideline recommendation.
In formulating recommendations, we were mindful of
their implications for use of resources although, unfortu-
nately, there is a lack of robust cost-effectiveness  analyses
for almost all ACS interventions within the Australian
context. Commentary regarding the key economic impli-
cations or other relevant system factors are included in the
‘Resources and other considerations’ section where
appropriate.
Aspects of care associated with a very limited evidence
base and reliant on consensus opinion, or where the impact of
interventions on clinical outcomes was considered to be
modest, are highlighted in the ‘Practice advice’ sections of
the guideline. While medication dosing is generally pro-
vided, clinicians are advised to refer to additional resources
such as the Australian Medicines Handbook for relevant
contraindications, precautions, drug interactions and
adverse effects.
The writing groups were aware that much of the evidence
has focussed on ‘hard’ clinical events such as mortality,
recurrent MI and stroke. As a consequence, the recommen-
dations and practice advice are strongly influenced by this
literature, which has been used to generate estimates of
treatment effect within the benefits and harms commentaries.
However, within clinical practice, it is recognised that these
endpoints are not universally valued as the highest priority
by patients when compared with other outcomes such as
quality of life. It is also recognised that the evidence base for
ACS care is very limited in regards to older patients with
substantial multi-morbidity, which precludes specific recom-
mendations being made for this patient group for most ACS
interventions. In such circumstances, users of these guide-
lines must rely on their own clinical judgment and a shared
decision-making process involving individual patients that
recognises their values and preferences. Furthermore, clini-
cal decisions should take into account the cultural and lin-
guistic diversity of Australia’s community, in particular the
Aboriginal and Torres Strait Islander community. Practice
advice sections include relevant comments wherever pub-
lished research has specifically focussed on such patients.
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Chest Pain
The single most important consideration in the assessment of
patients presenting with chest pain to an emergency medical
setting is to identify all patients with ACS or another life-
threatening condition. The inappropriate discharge of patients
with acute MI (AMI) and unstable angina (UA) from the
emergency department (ED) is associated with a substantial
increase in mortality compared with admitted patients [14]
[15] [16]. Thus, the sensitivity and negative predictive value
(NPV) of Suspected ACS Assessment Protocols (Suspected
ACS-AP) for the exclusion of ACS is paramount. It is equally
important to use rapid and efficient assessment protocols that
maximise specificity and positive predictive value (PPV) for
ACS in reducing unnecessary investigations and minimising
delays in the decision to discharge or admit from the ED.
Patients with ACS may present with a variety of typical
(e.g. chest pain) and atypical (e.g. fatigue) symptoms (Refer
to warning signs of a heart attack http://heartfoundation.
org.au/your-heart/heart-attack-warning-signs). The most
frequent symptoms of ischaemia other than chest discomfort
include shoulder, arm, jaw and upper abdominal pain; short-
ness of breath; nausea; vomiting and sweating (diaphoresis).
While there are many causes for chest pain and other
symptoms of possible AMI, the recommendations in this
section of the guidelines relate to patients with symptoms
suggestive of a coronary origin and in whom a diagnosis of
an ACS (AMI or UA) has to be considered. It is beyond the
scope of these recommendations to provide detailed assess-
ment, investigation and management strategies for all con-
ditions causing chest pain.
2.1. Initial Evaluation
Chest pain assessment is a time critical, hierarchical diagnos-
tic process based upon the history of the presenting com-
plaint, serial electrocardiographs (ECGs), serial biomarkers
for myocardial necrosis and an assessment of the patient’s
risk of having an ACS. The chest pain diagnostic process can
be represented by a stepped series of clinical questions:
1. Does this patient have a ST elevation MI (STEMI)? (Rule-
in STEMI)
2. What alternative life-threatening or other high-risk con-
ditions (e.g. aortic dissection, pulmonary embolus) need
to be considered in the differential diagnosis, especially
in the presence of cardiac biomarker elevation?
3. Does this patient have evidence of non-ST-elevation ACS
(NSTEACS)? (Rule-in NSTEMI/UA)
4. Does the patient have symptomatic obstructive coronary
artery disease (CAD)? (Rule-in angina)
5. Can patients at low likelihood of major adverse cardiac
events (MACE) be identified with a high degree of cer-
tainty (>99%)? (Rule-out high-risk patients)
6. Does the patient understand what to do in the event of
future episodes of chest pain or other symptoms after
discharge?2.1.1. Outpatient Presentation
Initial clinical assessment including history, examination,
ECG and single troponin testing are unable to exclude a
diagnosis of ACS by themselves. For this reason, patients
who present to primary care physicians or to clinicians in
other outpatient settings with chest pain (within 24 hours)
and suspected ACS should be referred as soon as possible to
the ED or a facility capable of definitive risk stratification and
diagnosis of ACS. Patients presenting with high-risk features
such as ongoing chest pain, dyspnoea, syncope/presyncope
or palpitations should be referred immediately to the ED. For
these patients, the goals of initial management include estab-
lishing the diagnosis with an ECG if available, and ensuring
immediate access to cardiac defibrillation where possible. For
this reason, patients should not drive themselves to the ED
and transport by emergency medical services is recom-
mended. Referral to ED should not depend on troponin
testing. Care should be initiated where possible and includes
administering aspirin and sublingual GTN in the absence of
contraindications (i.e. avoid IM injections) (See 2.3.1.1-
2.3.1.2).
2.1.2. Emergency Department
Presentation
Patients with suspected ACS must be evaluated rapidly to
identify patients with life-threatening non-ACS causes for
their acute presentation, quantify risk for ACS and promptly
institute appropriate management. Evidence-based clinical
pathways that guide assessment and management of patients
presenting with acute chest pain or other symptoms sugges-
tive of an ACS should be used. The Australasian Triage Scale
recommendation for patients presenting to the ED with chest
pain is to commence assessment within 10 minutes of pre-
sentation (i.e. Category 2 priority). Historical features may
alter estimates of pre-test probability for ACS, but no feature
or combination of features alone rules out ACS in the absence
of further investigations. Consideration should be given to
patient cohorts in whom atypical presentations of ACS are
more frequently encountered (e.g. people with diabetes,
women, older patients, those with mental-illness, those from
culturally and linguistically diverse (CALD) populations,
and Aboriginal and Torres Strait Islander peoples).
2.1.3. Initial ECG and Assessment
Recommendation: It is recommended that a patient with
acute chest pain or other symptoms suggestive of an ACS
receives a 12-lead ECG and this ECG is assessed for signs of
myocardial ischaemia by an ECG-experienced clinician
within 10 minutes of first acute clinical contact. (NHMRC
Level of Evidence (LOE): IIIC; GRADE strength of recom-
mendation: Strong).
Rationale: This initial assessment is to rapidly identify
patients with an acute STEMI, for whom emergency reperfu-
sion is clinically appropriate, and who require immediate acti-
vation of a defined STEMI pathway. (Refer to Section 3.1.1).
Initial assessment may also disclose patients with a high
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confirmatory investigation and appropriate management [17]
(Refer to Section 3.1.2and 3.2). There is limited evidence explor-
ing optimum timing of ECG acquisition and interpretation.
Benefits and harms: Approximately 2–5% of all patients with
possible cardiac chest pain have a STEMI, for whom delays in
identification and initiation of optimum treatment incur sig-
nificant morbidity and mortality (Refer to Section 3.1.1).
Resources and other considerations: Training in ECG acquisi-
tion is required for all health services. Interpretation should be
performed by an experienced clinician. Computer-assisted
interpretation of the ECG may increase diagnostic accuracy,
particularly for STEMI, among clinicians less experienced in
reading ECGs. In some settings (e.g. rural and remote areas),
ECG interpretation may be supported by linking local clini-
cians with experienced clinicians via one or other telemedi-
cine modalities (fax/telephone, digital ECG network, video
consultation) within a clinical network [18,19].
Practice Advice
2.1.3.1. Serial ECGs should be taken every 10-15 minutes
until the patient is pain-free and compared in sequence
and, where possible, with pre-existing ECGs.
2.1.3.2. Blood samples for biomarkers (cardiac troponin being
preferred) should be drawn on presentation (Refer to Section
2.5).
2.1.3.3. A chest X-ray is recommended in the assessment for
cardiac enlargement and identification of other non-coronary
causes of chest pain where the diagnosis is yet to be estab-
lished, though the utility of this investigation may be limited.
If a recent chest X-ray is available for review, repeat radio-
logical investigation may not be required.
2.2. Differential Diagnosis
The differential diagnosis of patients with chest pain is broad
and includes non-ACS conditions that may be associated
with ECG changes and normal or elevated troponin values
(Table 3 and Refer to Section 3.1.3: Type 2 AMIs). In theTable 3 Differential diagnosis of causes of chest pain
Ischaemic cardiovascular causes  ACS (e.g. acute myocar
 Stable angina
 Severe aortic stenosis
 Tachyarrhythmia (atrial
Non-ischaemic cardiovascular
causes of chest pain
 Aortic dissection (tear b
aortic aneurysm
 Pulmonary embolism
 Pericarditis and myocar
 Gastrointestinal causes 
pancreatitis, biliary disea
Non-cardiovascular causes  Musculoskeletal causes
 Pulmonary (e.g. pneum
 Other aetiologies (e.g. sabsence of ECG evidence consistent with STEMI, potentially
treatable, life-threatening conditions that should always be
considered in the differential diagnosis of chest pain include
aortic dissection, pulmonary embolism and tension pneumo-
thorax. Non-life-threatening causes for chest pain that should
be considered include gastro-oesophageal pathology, pleur-
itis and other pulmonary disease, muscular and skeletal
causes including costochondritis, and herpes zoster. In addi-
tion, patients with myocardial oxygen supply–demand mis-
match due to non-atherosclerotic and non-coronary
conditions (e.g. Type 2 MI, Refer to Section 3.1.3) may also
present with chest pain but who require a different manage-
ment pathway to patients with type 1 MI (i.e. plaque
rupture).
2.3. Initial Clinical Management
Practice Advice
2.3.1.1. Oxygen Supplementation. There are no randomised
comparisons of the routine use of oxygen therapy versus
room air that demonstrate improvements in clinical outcomes
in patients with suspected or confirmed ACS. A randomised
comparison has suggested an increase in infarct size with
routine supplemental oxygen among patients who are not
hypoxic [20]. The routine use of oxygen therapy among
patients with a blood oxygen saturation (SaO2) >93% is not
recommended, but its use when the SaO2 is below this level is
advocated despite the absence of clinical data [21–24]. How-
ever care should be exercised in patients with chronic obstruc-
tive airways disease where the target SaO2 is to be 88-92%.
2.3.1.2. Initial pharmacotherapy. In the presence of ongoing
chest pain, nitro-glycerine (GTN) sublingual tablet (0.3-
0.6 mg) or spray (0.4-0.8 mg) should be administered every
5 minutes for up to three doses if no contraindications exist
(such as hypotension). If the symptoms are unrelieved,
assessment for the need for intravenous (IV) GTN and/or
alternative therapy should be made. In the absence of contra-
indications, it is reasonable to administer titrated morphinedial infarction, unstable angina)
 or ventricular)
etween the layers of the wall of the aorta) and expanding
ditis
(e.g. gastro-oesophageal reflux, oesophageal spasm, peptic ulcer,
se)
 (e.g. costochondritis, cervical radiculopathy, fibrositis)
onia, pleuritis, pneumothorax)
ickle cell crisis, herpes zoster)
Table 4 Risk Scores: TIMI score [28] (Chest pain section), GRACE Score [29] and CRUSADE score [115] (ACS risk
stratification section)
Clinical risk scores
TIMI Risk Score for NSTEACS (points 0–7) GRACE Risk Score (points 2–306) CRUSADE Risk Score (points 0–96)
Purpose Ischaemic risk and ruling out ACS Ischaemic risk Bleeding risk
Components Age  65 1 Age 0–91 Haematocrit % 0–9
Aspirin use in the last 7 days 1 Heart rate 0–46 Heart rate 0–11
52 angina episodes within last 24 hrs 1 Systolic BP 0–63 Systolic BP 0–63
ST changes of at least 0.5 mm in
contiguous leads
1 Creatinine 2–31 eGFR 0–36
Elevated serum cardiac biomarkers 1 Cardiac arrest at admission 43 Female 8
Known CAD (coronary stenosis 550%) 1 ST segment deviation 30 Heart failure 7
Elevated cardiac markers 15 Diabetes 6
At least 3 risk factors for CAD, such as: 1 Killip class 0–64 Peripheral vascular disease 6
- Hypertension >140/90 or on anti-
hypertensives
- Current cigarette smoker
- Low HDL cholesterol (< 40 mg/dL)
- Diabetes mellitus
- Family history of premature CAD
Score
interpretation
% risk at 14 days of all-cause mortality,
new or recurrent MI, or severe recurrent
ischaemia requiring urgent revascularisation
% risk by 6 months for
all-cause mortality
% risk of in-hospital major
bleeding
 0–1=4.7% risk  60–100 = 3% risk  <20 = 3% risk
 2=8.3% risk  100–140 = 8.0% risk  20–30 = 6% risk
 3=13.2% risk  140–180 = 20% risk  30–40 = 10% risk
 4=19.9% risk  >180 = >40% risk  >40 = >15% risk
 5=26.2% risk Derived from international
registry of ACS patients
Derived from US-based registry
of ACS patients 6–7=at least 40.9% risk
Derived from clinical trial patients
Reference Antman EM, Cohen M, Bernink PJ,
McCabe CH, Horacek T, Papuchis
G, et al. The TIMI Risk Score for
Unstable Angina/Non-ST Elevation
MI, JAMA, 2000; 284:335–42
Fox KAA, Dabbous OH,
Goldberg RJ, et al. Prediction
of risk of death and myocardial,
infarction in the six months
after presentation with acute
coronary syndrome: prospective
multinational observational study
(GRACE), BMJ, 2006:333:1091.
Subherwal S, Bach RG,
Chen AY, et al. Baseline
Risk of Major Bleeding in
Non-ST-Segment-Elevation
Myocardial Infarction:
The CRUSADE (Can Rapid
risk stratification of Unstable
angina patients Suppress
ADverse outcomes with
Early implementation of the
ACC/AHA guidelines)
Bleeding Score. Circulation.
2009; 119:1873–82
Implementation Easily implemented in paper format
but web-based tools also available
(Reference: TIMI Risk Score Calculator
for UA/NSTEMI.
http://www.timi.org/index.php?page
=calculators)
Implementation is more
easily undertaken using
electronic platforms (Reference:
https://www.outcomes-
umassmed.org/grace/acs_
risk/acs_risk_content.html)
Implementation is more
easily undertaken using
electronic platforms (Reference:
http://www.crusadebleedingscore.org)
ACS, acute coronary syndromes: BP, blood pressure; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction
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discomfort at any time during the initial management (note:
morphine administration has been shown to slow absorption
of oral medications including ticagrelor). Non-steroidal anti-
inflammatory medications should not be given due to the
increased risk of MACE [25,26] in patients subsequently
shown to have ACS.
2.3.1.3. Initial Aspirin Therapy. In all patients with possible
ACS and without contraindications, aspirin (300 mg orally,
dissolved or chewed) should be given as soon as possible
after presentation.
2.3.1.4. Other Anti-Thrombotic Therapies. Additional anti-
platelet and anticoagulation therapy or other therapies such
as beta blockers should not be given to patients without a
confirmed or probable diagnosis of ACS.
2.4. Risk Scores and Clinical Assessment
Protocols
The process of risk stratification is to assist in estimating the
probability of ACS and ACS-related morbidity and mortality.
In patients presenting acutely with chest pain this process
aids evaluation, treatment (drug therapies or an early inva-
sive therapeutic approach) and disposition (cardiac care unit,
monitored environment, short stay units or discharge). The
process of risk stratification reduces unnecessary investiga-
tions and therapies and decreases avoidable inpatient admis-
sions among low-risk patients [27] while identifying higher
risk patients requiring longer periods of observation or fur-
ther investigation before discharge.
Risk scores usually incorporate elements of history,
examination findings, ECGs and biomarker values [28–
32]. No risk score in isolation identifies patients at low risk
for ACS who can be safely discharged without further
investigation (Refer to Table 5). Suspected ACS Assessment
Protocols (Suspected ACS-AP), sometimes called acceler-
ated diagnostic protocols (ADPs), integrate risk scores and
define a process of assessment that includes recommenda-
tions for biomarker testing intervals for patients with pos-
sible cardiac symptoms.
2.4.1. Use of Clinical Assessment
Protocol
Recommendation: A patient presenting with acute chest
pain or other symptoms suggestive of an ACS should
receive care guided by an evidence-based Suspected
ACS Assessment Protocol that includes formal risk strati-
fication. (NHMRC Level of Evidence (LOE): IA; GRADE
strength of recommendation: Strong).
Rationale: A single meta-analysis, two randomised con-
trolled trials (RCTs) and a large number of prospective obser-
vational trials have been published describing risk scores and
Suspected ACS-APs. Risk scores include those originally
derived from cohorts with ACS (TIMI [33,34,35,36,37],
GRACE [38–40]) and newer tools derived from cohorts with
undifferentiated chest pain (HEART [41], EDACS [31], MACS[32] rules). Formal risk stratification allows quantification of
risk of MACE in patients with chest pain up to 30 days after
presentation. However, if used alone, these scores lack the
ability to define a low-risk population suitable for limited
assessment and early discharge from ED. For example, the
NPV for MACE for low-risk patients using the HEART score
is 96-98% (i.e. up to 4% missed MACE rate) [30,37,41,42].
Some risk scores have been incorporated into defined
Suspected ACS-APs (ADAPT [43], modified-ADAPT [36],
HEART pathway [44], EDACS-ADP [31]). Several Suspected
ACS-APs facilitate the early disposition of patients identified
as low risk for 30-day MACE. The pathways with consis-
tently high NPV (>99%) for MACE in validation studies, and
which allow identification of patients safe for early discharge,
include the ADAPT (using sensitive troponin assays), modi-
fied-ADAPT (using highly sensitive troponin assays) rules
[36,43], and the HEART pathway [45]. The EDACS-ADP [31],
MACS rule [32], and North American chest pain rule [46]
currently have limited validation to support widespread use.
Risk scores such as the TIMI score, GRACE score and HEART
score cannot rule-out ACS in primary care or hospital-based
settings. Suspected ACS-APs have not been assessed in a
primary care setting [47]. The estimates of benefits and harms
listed below are based on these Suspected ACS-APs (Table 5).
Benefits and harms: Formal risk assessment of patients with
symptoms of possible ACS supports quantification of MACE
risk within 30 days of assessment, may reduce misdiagnosis
and inappropriate discharge from ED of patients with ACS
from 2-8% to less than 1%, and increase absolute rates of early
discharge of low-risk patients from ED by up to 20-40%
[43,48,49]. Use of Suspected ACS-APs can assist in identify-
ing low-risk patients (up to 40% of all patients presenting to
ED with chest pain) for whom early discharge from ED may
be appropriate.
Resources and other considerations: Use of formal risk scores
and Suspected ACS-APs in assessing patients with chest pain
should be documented and may be aided by the use of
electronic decision aids. Suggested pathways/protocols
and methods for monitoring their effectiveness are provided
in Figures 1–3. Such documentation may inform local audit
and quality improvement processes aimed at optimising
appropriateness of care. Accelerated management and dis-
position of patients as a result of formal risk scoring inte-
grated with Suspected ACS-APs could be highly cost-
effective.
Practice Advice
2.4.1.1. Implementing a Suspected ACS-AP. In choosing
among different Suspected ACS-APs, for hospitals using
sensitive or highly sensitive troponin assays, the ADAPT
or modified-ADAPT protocol, respectively identifies low-
risk patients (<1% MACE at 30 days) on the basis of negative
troponin measurement at both 0 and 2 hours, TIMI score of 0
(ADAPT) or TIMI score of 0 and 1 (Modified-ADAPT), and
no ischaemic changes on ECG at both 0 and 2 hours. Sug-
gested implementation of an ADP is presented in the Figures
1–3.
Table 5 Performance of various risk scores and Clinical Assessment Protocols in the management of suspected ACS#
Tool ^ Sens Spec NPV PPV LR Proportion in risk group References
High risk Risk Score (Positive Likelihood ratios)
HFA – high risk 78 - 100 8 – 72 98 23 2.2-2.7 33-59% [6,36,200]
TIMI 5-7 22 96.4 92 39 6.8 1-5% [7,36]
GRACE 100 69 76 96 24 2.9 28% [36]
HEART score 7-10 13 [30,37,201,202]
Low risk Risk Score (Negative Likelihood ratios)
TIMI 0-1 89 - 98 13 - 56 96 - 99 12 - 20 0.19 23 – 51% [30,36,200,203,204]
HEART score 58- 100 32 - 85 96-99 4-34 0.05-0.15 28 -34% [30,41,42,205,206]
HFA - Low 100 1 100 10 0.4 1-17% [7,36]
GRACE 50 99 27 100 13 0.04 24% [36]
GRACE FFE score 93-100 35-68 100 0.4 [39,207]
MACS rule 98 99 0.09 [32,208]
Low risk Suspected ACS-APs (Negative Likelihood ratios)
ADAPT ADP* 100 23 100 19 0.014 20% [43,108]
Modified ADAPT ADP* 99 47-49 100 26-28 0.17 39-42% [49,209]
HEART Pathway^^ 99-100 99-100 0.04 20-82% [45,48]
EDACS-ADP* 99- 100 50-59 0.011 42 - 51 [31]
NACPR (age cut-off 50) 100 20.9 100 0 18% [46]
TRUST ADP 99 43 100 14 0.029 40% [210]
TRAPID 97 75 99 44 0.044 17% [86]
Note: All values are rounded to nearest whole number
#Table was modified from Fanaroff AC, et al. ‘‘Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic
Review.’’ JAMA. 2015;314(18):1955-65. [211]
^ Abbreviations and acronyms:
PPV: positive predictive value;
NPV: negative predictive value;
Sens: sensitivity;
Spec: specificity;
HEART: History, Electrocardiogram, Age, Risk Factors, Troponin;
HFA/CSANZ:The Heart Foundation of Australia and Cardiac Society of Australia and New Zealand (2006 guideline);
ADAPT: 2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker;
EDACS: Emergency Department Assessment of Chest pain Score;
NACPR: North American Chest Pain Rule;
ADP: Accelerated Diagnostic Protocol;
FFE: Freedom From Event;
LR: Likelihood Ratio;
TIMI: Thrombolysis in Myocardial Infarction.
Endpoints differ with some studies reporting MACE or cardiac events at 30 days*. Others report events to 6 weeks^^.
908 D.P. Chew et al.2.4.1.2. Local Validation of Suspected ACS-AP. Some
centres may choose to assess and implement an alternate
strategy to the recommended Suspected ACS-AP for the
assessment of ED patients with possible ACS. The perfor-
mance of any pathway for suspected ACS depends on the
incidence of ACS within the local ED population and the sub-
population among whom the pathway is applied. Validation
of an alternate locally implemented Suspected ACS-AP,
including the assessment of 30-day mortality and represen-
tation with confirmed ACS in all patients presenting with
chest pain, is recommended (Refer to Section 7).2.4.1.3. Identification of Patients at High Risk for a Cardiac
Cause of Chest Pain. The clinical characteristics of patients at
high risk for a cardiac cause of chest pain (including ACS and
other cardiac diagnoses) are described in Table 6. More than
25% of patients with these high-risk features will have a
confirmed diagnosis of ACS and should be referred for
inpatient investigation [5]. Several recognised high-risk
groups of patients are underrepresented in current trials,
including patients over the age of 85 years, patients with
renal disease, HIV, familial hypertriglyceridaemia, rheuma-
toid arthritis or mental health disorders, and certain ethnic
Figure 1 Example of Assessment Protocol for suspected ACS using point-of-care assays.
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present more commonly than men with atypical symptoms.
A higher index of suspicion of ACS should be exercised when
assessing risk in such situations.
2.4.1.4. Identification of Patients at Low Risk for a Cardiac
Cause of Chest Pain. A central consideration in determining
which Suspected ACS-APs are most appropriate for clini-
cal use is the miss rate (false negative rate) for MACE that
is acceptable to both patients and clinicians. One study
has defined the miss rate for MACE for ED physicians as<1% at 30 days following ED presentation [50]. Little is
known about patient expectations. Shared decision-making
tools have reduced rates of exercise testing and hospital
admission in patients with undifferentiated chest pain
[51,52].
2.5. Biomarkers
Cardiac troponins are the most sensitive and specific bio-
marker for myocardial injury and necrosis. Both troponin I
and T subtypes are cardio-specific. Troponin levels become
elevated in the blood stream within 1-3 hours after AMI and
Figure 2 Example of Assessment Protocol for suspected ACS using a sensitive lab-based assay.
910 D.P. Chew et al.may remain elevated for up to 14 days. The rise and/or fall of
troponin with at least one value greater than the 99th percen-
tile is a key criterion for diagnosis of MI according to the 2012
Third Universal Definition of MI [53]. For the vast majority of
patients being investigated for possible AMI, a rising pattern
is suggestive of AMI. In patients who present late following
AMI, troponin elevations may have peaked, and in this
context a fall in troponin is significant.
Five clinical presentations of MI have been defined on the
basis of pathological, clinical, and prognostic factors (Refer to
Section 3.1.2 and Table 7). In the clinical setting of patientswith chest pain and identification of possible AMI, Type 1 MI
(spontaneous MI related to atherosclerotic plaque rupture,
with ulceration fissuring, erosion or dissection) is the focus of
treatment strategies. Increasingly sensitive assays (highly
sensitive troponin assays) have reduced the time interval
before an elevated troponin value can be detected in the
setting of AMI, and may increase the diagnostic rate of
NSTEMIs [54–56]. In addition, highly sensitive troponin
assays have reduced the time interval over which a clinically
significant change in serial troponin levels can be reliably
detected.
Figure 3 Example of Assessment Protocol for suspected ACS using a highly sensitive lab-based assay.
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Recommendation: Using serial sampling, cardiac-specific
troponin levels should be measured at hospital presenta-
tion and at clearly defined periods after presentation using
a validated Suspected ACS-AP in patients with symptoms
of possible ACS [57–60]. (NHMRC Level of Evidence
(LOE): 1A; GRADE strength of recommendation: Strong).
Rationale: Newer, more sensitive troponin assays can detect
increasingly lower concentrations of troponin in the settingof myocardial necrosis, thus allowing earlier detection of
patients with AMI. In addition, Suspected ACS-APs have
been derived using both sensitive and highly sensitive tro-
ponin assays that support the early rule-in and rule-out of
AMI when applied as per protocol. Serial measurement of
cardiac-specific troponin levels is necessary to accommodate
differences in time of presentation and to identify instances
of acutely or chronically elevated troponin attributable to
factors other than ACS. While the quality of evidence is
moderately high, consideration must be given to the varying
Table 6 Risk classification for possible cardiac causes of chest pain
High risk  Ongoing or recurrent chest discomfort despite initial treatment
 Elevated cardiac troponin level
 New ischaemic ECG changes (such as persistent or dynamic electrocardiographic changes of ST
segment depression  0.5 mm, transient ST-segment elevation (0.5 mm) or new T-wave inversion
2 mm in more than two contiguous leads; or ECG criteria consistent with Wellens syndrome
 Diaphoresis
 Haemodynamic compromise — systolic blood pressure <90 mmHg, cool peripheries, Killip Class >I, and/or
new-onset mitral regurgitation
 Sustained ventricular tachycardia
 Syncope
 Known left ventricular systolic dysfunction (left ventricular ejection fraction <40%)
 Prior AMI, percutaneous coronary intervention, or prior CABG
Low risk  age <40 years
 symptoms atypical for angina
 remain symptom-free
 absence of known CAD
 normal troponin level
 normal ECG
Intermediate risk  Neither high-risk nor low-risk criteria.
ECG: electrocardiogram
CAD: coronary artery disease
CABG: coronary artery bypass grafting
Table 7 Universal classification of myocardial infarction [53]
Classification Descriptor
Type 1: Spontaneous MI Spontaneous MI related to atherosclerotic plaque rupture, ulceration, erosion,
or dissection with resulting intraluminal thrombus in one or more of the
coronary arteries leading to decreased myocardial blood flow or distal platelet
emboli with ensuing myocyte necrosis.
Type 2: MI secondary to an ischaemic imbalance Myocardial injury with necrosis where a condition other than CAD contributes
to an imbalance between myocardial oxygen supply and/or demand, e.g.
coronary endothelial dysfunction, coronary artery spasm, coronary embolism,
tachy-/bradyarrhythmias, anaemia, respiratory failure, hypotension, and
hypertension with or without LVH.
Type 3: MI resulting in death when biomarker
values are unavailable
Cardiac death with symptoms suggestive of myocardial ischaemia and
presumed new ischaemic ECG changes or new LBBB, but death occurring
before blood samples could be obtained, before cardiac biomarker could rise,
or when cardiac biomarkers were not collected.
Type 4a: MI related to percutaneous coronary
intervention (PCI)
MI associated with PCI (refer to reference for specific criteria)
Type 4b: MI related to stent thrombosis MI associated with stent thrombosis (refer to reference for specific criteria)
Type 5: MI related to coronary artery bypass
grafting (CABG)
MI associated with CABG (refer to reference for specific criteria)
CAD: coronary artery disease
LVH: left ventricular hypertrophy
LBBB: left bundle branch block
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nin assays.
Benefits and harms: The effects of routinely implementing
troponin testing within a validated Suspected ACS-AP on the
rate of missed MI and early mortality are difficult to quantify
due to study heterogeneity and varying levels of expertise
within current practice [27,61].
Resources and other considerations: Biomarker-based strate-
gies for the rule-in and rule-out of AMI have variable accu-
racy. Biomarker elevation portending a clinical diagnosis of
AMI may not occur in a small proportion of patients until 8–
12 hours after pain onset [62]. Our understanding about
timing of sampling with newer assays and differences
between assays is evolving [63,64]. Clinically usable strate-
gies must maintain safety, with missed MI rates 1% (NPV 
99%). Clinicians must understand the analytical and perfor-
mance characteristics of the local assay in use and the specific
Suspected ACS-APs used in their setting which incorporate
that assay. Of importance, quantitative comparisons cannot
be made between troponin I and troponin T, or between point-
of-care (POC) devices and laboratory based immunoassays.
Practice Advice
2.5.1.1. Definition of Elevation and Biomarker Evidence of
AMI. An elevated troponin value indicating myocardial
necrosis is one greater than the 99th percentile (upper refer-
ence level) for a specific assay [53]. For the diagnosis of AMI,
serial samples are required to determine a rise and/or fall in
values. The optimum change value for identification of AMI
is usually assay specific and depends on the degree of initial
elevation (if present), the time interval between consecutiveTable 8 Causes of troponin elevation*
Cardiac contusion, or other trauma including surgery, ablation, pacing
Congestive heart failure — acute and chronic
Coronary vasculitis, e.g. SLE, Kawasaki syndrome
Aortic dissection
Aortic valve disease
Hypertrophic cardiomyopathy
Tachy- or bradyarrhythmias, or heart block
Stress cardiomyopathy (Takotsubo cardiomyopathy)
Rhabdomyolysis with cardiac injury
Pulmonary embolism, severe pulmonary hypertension
Renal failure
Acute neurological disease, including stroke or subarachnoid haemo
Infiltrative diseases, e.g. amyloidosis, haemochromatosis, sarcoidosis, a
Inflammatory diseases, e.g. myocarditis or myocardial extension of end
Drug toxicity or toxins e.g. anthracyclines, CO poisoning
Critically ill patients, especially with respiratory failure or sepsis
Hypoxia
Burns, especially if affecting > 30% of body surface area
Extreme exertion
False positives: Cross reacting heterophile antibodies
*Life–threatening, non-coronary conditions highlighted in boldsamples, the time of pain onset and the possible presence of
non-ACS causes of elevated troponin (Refer to Section 3.1.2).
Absolute changes in nanograms per litre using highly sensi-
tive troponin assays have better diagnostic accuracy for AMI
than relative change values [65–67]. In patients with a high
clinical suspicion of ACS, troponin values below or close to
the 99th percentile, changes of  2–3 standard deviations of
variation around the initial value, depending on the assay,
should prompt additional testing, as this is unlikely to reflect
normal biological variability [53] [65]. Laboratory reports
should indicate whether clinically significant changes in
troponin values of a specific assay have occurred. It should
be noted that non-ACS causes of chest discomfort may also
result in a rise and fall in serial troponin levels (e.g. pulmo-
nary embolus, myocarditis and extreme exercise: See Table
8). False positive results due to analytical issues may be
detected by using an alternate assay.
2.5.1.2. Assays. Nomenclature used for describing assay
types may cause misunderstandings of assay capabilities
and performance that could lead to incorrect use of early
assessment strategies. The majority of cardiac troponin
assays are performed on automated platforms within cen-
tralised laboratories using sensitive or highly sensitive
assays. Without access to central laboratories or automated
assay platforms, POC assays are also in use and those with
highest sensitivity for detecting troponin are recommended
[68]. The analytical characteristics of assays as reported by
the manufacturers are available at <www.ifcc.org/media/
276661/IFCC%20Troponin%20Tables%20ng_L%20DRAFT
%20Update%20NOVEMBER%202014.pdf>, frequent defibrillator shocks
rrhage
nd scleroderma
o-/pericarditis
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(coefficient of variation) at the 99th percentile value 10%
and the ability to measure troponin concentrations below the
99th percentile that are above the assay’s limit of detection in
at least 50% (and ideally >95%) of healthy individuals [67,69].
All other troponin assays are labelled sensitive or contempo-
rary assays.
POC assays currently have lower analytical sensitivity for
detecting troponin, with no currently commercially available
assay meeting high sensitivity criteria [70] [71,72] [69,73]. The
shorter turnaround times for POC assays may aid further
management for patients with elevated values detected on
early (within 2 hours of presentation) or late (>12 hours)
sampling. In addition, serial sampling over 6–12 hours after
presentation may be used for the rule-out of AMI, while early
repeat testing (1-3 hours) in patients with initial troponin
elevation may be useful for documenting a rise/fall in tro-
ponin for ruling in MI. Strategies to use POC assay results in
isolation of an evidence-based Suspected ACS-AP in early
rule-out for AMI are insufficiently sensitive and cannot be
supported at this time. Decisions based on POC testing are
not recommended if laboratory troponin test results are
available within one hour of request.Table 9 Timing of troponin testing
Timing of sampling Strateg
0 hour
(single sample)
Patients whose pain and symp
prior to testing
(cut points are the assay-speci
0 hour
(single sample)
Patients with value <LoD of t
(not >99th percentile cut point
onset >3 hours^ [78,87,88]
0 and 1 hours after presentation Rule-in and rule-out AMI algo
(cut points are assay-specific a
0 and 2 hours after presentation ADAPT protocol [43]
Modified ADAPT protocol [49
(cut points are the assay-speci
0 and 3 hours after presentation Previous NHF protocol [9]
HEART pathway, [45,48]
(cut points are the assay-speci
0 and 6-12 hours after presentation Rule-in and rule-out AMI algo
[10]
(cut points are the assay-speci
LOD = limit of detection
AMI = Acute myocardial infarction
ADAPT = 2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pa
NHF = National Heart Foundation of Australia
HEART = History, Electrocardiogram, Age, Risk Factors, Troponin
# With concurrent clinical risk stratification
^ Reports on the use and outcomes of the biomarker strategy in clinical practice arePatients with suspected or proven ACS, in whom transfer
to another site is necessary, should have blood samples,
stored at 48 C, accompany them for repeat analysis using
the troponin assay used at that site.
2.5.1.3. Timing of Testing. The majority of patients with an
underlying diagnosis of AMI have elevated troponin values
within 3-6 hours of symptom onset, although some assays
may not show elevated values for up to 12 hours [54,74]
(Table 9). Despite improvements in troponin assay sensitivity
and use of Suspected ACS-APs, an initial troponin value
from a blood sample taken on ED presentation that is below
the 99th percentile of a sensitive or highly sensitive assay
cannot be used by itself for the rule-out of AMI [75,76].
Whether an initial value below the limit of detection for a
highly sensitive assay rules out AMI is yet to be established in
prospective studies that i) clearly delineate the time interval
between pain onset and collection of initial troponin [77–84],
and ii) report on the outcomes of this strategy utilised in
clinical care.
The time of symptom onset, even if reliable, does not define
the time point of coronary occlusion. Early rule-out bio-
marker strategies must incorporate serial samples that detecty# Assays
toms resolved 12 hours
fic 99th percentile)
Both sensitive and highly
sensitive assays
he specific assay
) and symptom
Highly sensitive assays
rithms [83,89,90]
nd not the 99th percentile)
Highly sensitive assay
,57]
fic 99th percentile)
Sensitive assays
Highly sensitive assays
fic 99th percentile)
Highly sensitive assays
Both sensitive and highly
sensitive-assays
rithms
fic 99th percentile)
Sensitive and point-of-care assays
in Symptoms Using Contemporary Troponins as the Only Biomarker
 not currently available
National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand 915a rising/falling pattern, timed from the initial sample taken
at ED presentation. Possible exceptions to this are patients
who are symptom-free for 12 hours prior to assessment, or
present >3 hours after symptom-onset with values less than
the limit of detection (LoD) using a highly sensitive troponin
assay. Additional troponin testing should be performed in
patients with ongoing or recurrent symptoms of ischaemia.
Validated rapid rule-in and rule-out algorithms for AMI
incorporated into Suspected ACS-APs and/or using highly
sensitive troponin assays may reduce the serial testing time
to one to two hours after presentation [57,83–86]. Incorpo-
ration of sensitive or highly sensitive troponin assay results
into the ADAPT- and modified ADAPT-ADP respectively
allows early (two hours after ED presentation) risk stratifi-
cation [43,49] (see Figures 2 and 3).
2.5.1.4. Cut Points for the Determination of an Abnormal
Troponin Value. While the universal definition of myocar-
dial infarction defines an elevated troponin value of greater
than the 99th percentile as abnormal, novel strategies often
report values in alternate troponin concentrations [78,83,87–
90]. Some strategies have been assessed in multiple large
cohorts and the results are reassuring in regards to safety
for the exclusion of AMI when the specific parameters are
met. Further research reporting the outcomes in clinical
practice of utilisation of such strategies are needed. The
evidence for the use of sex-specific reference ranges for high
sensitivity assays is evolving [91]. For females, the sex-spe-
cific cut point identifies patients at greater long-term risk of
adverse events [56,92,93]. Further research is needed to clar-
ify the optimum strategy for both males and females.
2.5.1.5. Other Biomarkers Beyond Troponin. Creatine
kinase myocardial enzyme (CK and CK-MB) and myoglobin
are not useful for the initial diagnosis of ACS where there is
access to troponin testing
2.5.1.6. Observation and Continuous ECG Monitoring.
Patients in whom symptoms have resolved, initial ECG
shows no ischaemic changes (including the absence of left
bundle branch block (LBBB)) and initial troponin value is
within normal reference range can be observed in an ED
observation unit or chest pain unit, and do not require con-
tinuous ECG monitoring. Reinstitution of ECG monitoring
should be considered for patients with subsequent elevation
of troponin on serial testing.
2.6. Further Diagnostic Testing
The aims of further diagnostic testing in patients with
resolved symptoms, non-ischaemic ECGs and normal serial
troponin values are to diagnose significant underlying CAD
and provide prognostic information. Increasingly, the utility
of such testing is questioned in patients at low risk for an
evolving ACS as defined by Suspected ACS-APs, which
includes those with atypical symptoms, no or very few vas-
cular risk factors, no arrhythmias or clinical features sugges-
tive of arrhythmia and no prior heart disease. Evidencesuggests that such patients are at negligible risk of MACE
and further testing is not warranted [94–96] and may actually
be harmful.
In patients defined as having intermediate risk, such as
those with more typical pain and/or multiple risk factors,
further testing may be safely performed during admission or
shortly after discharge. Patients at high risk, in whom one in
three will prove to have ACS, and who include those with
classical crescendo angina symptoms and/or prior history of
CAD, should be investigated early, as an inpatient, and
managed empirically as having ACS.
Various studies have shown that a normal exercise ECG
(based on achieving more than 85% predicted maximum
heart rate), dobutamine or dipyridamole stress echocardio-
gram or coronary computerised tomography angiography
(CTCA) has high NPV for ischaemia and is associated with
excellent patient outcomes [97–100]. Several high quality
systematic reviews and one high quality RCT for CTCA
[61,99,101–105] attest to its diagnostic accuracy for CAD in
patients with suspected ACS. Although both stress imaging
and CTCA have greater diagnostic accuracy [106], exercise
ECG is a widely available, low-cost method which, in
patients with an interpretable ECG and who can exercise,
can identify patients at low risk for MACE [100]. However,
the quality of evidence for all objective testing strategies is
inconsistent and limited to the period prior to the advent of
highly sensitive troponin assays. If clinical suspicion is high
despite meeting clinical criteria for very low risk, patients
should continue to be evaluated according to local protocols
for intermediate- or high-risk patients.
2.6.1. Selection of Patients for Further
Diagnostic Testing
(a) Recommendation: Non-invasive objective testing is
recommended in intermediate-risk patients, as
defined by a validated Suspected ACS-AP, with nor-
mal serial troponin and ECG testing and who remain
symptom free (NHMRC Level of Evidence (LOE): IA;
GRADE strength of recommendation: Weak).
(b) Recommendation: Patients in whom no further objec-
tive testing for CAD is recommended are those at low
risk, as defined by a validated Suspected ACS-AP: age
<40 years, symptoms atypical for angina, in the
absence of known CAD, with normal troponin and
ECG testing and who remain symptom free (NHMRC
Level of Evidence (LOE): III-3C; GRADE strength of
recommendation: Weak).
Rationale: A small but significant proportion (<4%) of
patients presenting with possible cardiac chest pain in whom
biomarker and ECGs are normal have UA and underlying
CAD [5]. Important diagnostic and prognostic information is
derived from objective testing which may guide further
diagnostic procedures and support therapeutic interventions
to alter short- and long-term coronary risk.
Benefits and harms: The benefit of diagnosing UA is to allow
the timely instigation of therapy to improve prognosis. The
916 D.P. Chew et al.harms include needless downstream interventions (includ-
ing invasive strategies and each with their own risks) and
provocation of patient anxiety in response to an incorrect or
highly unlikely diagnosis of coronary-related pain. Appro-
priate identification of pre-test risk is required to optimally
balance the benefits and harms.
Resources and other considerations: Considerable healthcare
resources may be consumed by the inappropriate use of
testing procedures in patients with low pre-test probability
of ACS. The aim of improving short- and long-term outcomes
in patients with UA must be balanced against the cost effec-
tiveness of downstream interventions [5]. Conversely, con-
straints on the availability and expertise of local investigative
facilities in regional and smaller community hospital settings
can hamper appropriate evaluation of patients at higher risk
in the absence of service networks which link these locales
with expert advice.
Practice Advice
2.6.1.1. Test Selection – Functional Versus Anatomical. The
choice of objective test is based on patient criteria (ECG
interpretability, ability to exercise), diagnostic accuracy, local
expertise and available technologies, and risks and costs
associated with specific investigations, including equipment,
radiation and contrast risks. Treadmill exercise testing is
useful in patients without contraindications and able to exer-
cise, due to widespread access, simplicity, low risk, low cost
and understanding of its utility in prognostication by clini-
cians; however its overall benefit is not clearly defined. Stud-
ies available prior to the availability of troponin assays
showed NPV of 97-99% for AMI and death [100]. Anatomical
investigations including CTCA and functional imaging tests
such as stress echocardiography are sensitive for the diagno-
sis of CAD. While there is evidence that stress echocardiog-
raphy and CTCA are superior to exercise stress testing
[61,99,107], access to these modalities is limited in many
ED settings and the overall incremental benefit is not proven.
Whether CTCA can be used, as part of a Suspected ACS-AP,
to identify a subset of low-risk patients with normal coronary
arteries who do not need delayed troponin testing is under
active investigation [61,99,107], although cost, access,
resource implications and risk of radiation exposure to large
numbers of low risk patients may counterbalance any
benefits.
Note: Clinical scenarios where ECG-only exercise testing
may be inappropriate or provide sub-optimal diagnostic
accuracy: bundle branch block; left ventricular hypertrophy
(LVH) on voltage criteria or previous LV imaging; digoxin
therapy; mitral valve prolapse; severe valvular disease; pre-
excitation syndromes; severe cardiomyopathy; pacemaker in
situ; women <50 years; anaemia (Hb <90 g/dL); uncorrected
electrolyte abnormalities; inability to exercise to achieve max-
imum predicted heart rate; concomitant beta blocker therapy.2.6.1.2. Timing of Testing. High-risk patients require fur-
ther objective testing during the index admission. Interme-
diate risk patients may be safely accelerated for early
inpatient testing or discharged for outpatient testing ideally
within 7 days, although acceptable up to 14 days after pre-
sentation. Investigation prior to discharge from the ED is
desirable among patients with characteristics associated with
significant failure to re-attend for medical review given the
higher rates of MACE in such patients [100]. Low risk
patients may not require any further investigation (Refer
to Section 2.6.1.3) [43,49,108].
In patients without high-risk features and with negative
biomarker and ECG testing, and who remain symptom-free,
the risk of an ACS event within 30 days is <4%. A high
clinical suspicion is needed in identifying patients who
are at high risk for serious adverse events but who have
initial normal troponin and ECG testing (e.g. classical cre-
scendo angina symptoms, such as increasing episodes of
ischaemic symptoms with less exercise or lasting longer).
For a proportion of non-high-risk patients, well-defined
accelerated strategies may allow early inpatient testing or
delayed outpatient testing up to 30 days after presentation
[43,49,108].
2.6.1.3. Criteria for Patients Requiring no Further Testing.
The criteria used to define low-risk patients in whom further
investigation may not be warranted has varied in studies,
and criteria we have defined may be contested [94–96]. If
clinical suspicion is high (e.g. patients of Aboriginal and
Torres Strait Islander decent) despite meeting clinical low-
risk criteria, patients should continue to be evaluated accord-
ing to local protocols for intermediate or high-risk patients.
2.7. Representation With Symptoms
Patients who represent to ED with possible symptoms of
NSTEACS within 30 days and who have not already under-
gone objective testing may warrant consideration of exercise
testing, stress echocardiography, nuclear perfusion scanning
or CTCA, as well as a detailed re-appraisal for alternate
diagnoses. If representation has occurred after prior negative
exercise testing, use of investigations with greater sensitivity
and specificity should be considered.
2.8. Discharge Advice
On discharge from ED, patients who have been assessed for
possible cardiac chest pain should receive a management
plan which includes information about their likelihood of
ACS, advice about representation with recurrent symptoms,
hospital follow-up arrangements regarding subsequent test-
ing and timing of the test (if required), and review by their
local general practitioner (GP) for risk factor modification.
Consideration should be given to discharge with aspirin and
GTN as required.
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and Risk Stratification of Acute
Coronary Syndromes
The following sections pertain to those patients where ACS is
the working or confirmed diagnosis.3.1. Diagnostic Considerations
3.1.1. ST-segment Elevation Myocardial
Infarction (STEMI)
ST-segment elevation on the 12-lead ECG suggests an acute
epicardial coronary occlusion as a cause for the clinical pre-
sentation. The diagnostic criteria are a clinical history of
typical chest discomfort or pain of 20 minutes duration
(which may have resolved by the time of presentation)
and ECG criteria with persistent (>20 minutes) ST segment
elevation in 2 contiguous leads of:
 2.5 mm ST elevation in leads V2-3 in men under 40 years,
or
 2.0 mm ST elevation in leads V2-3 in men over 40 years, or
 1.5 mm ST elevation in V2-3 in women, or
 1.0 mm in other leads
 or development of new onset left bundle-branch block
(LBBB) [109].
In patients with LBBB, the modified Sgarbossa Criteria is
useful in identifying MI: ST elevation 1 mm concordant
with QRS (5 points); ST depression  1 mm in lead V1-V3
(3 points); ST elevation  5 mm discordant with QRS (2
points) (i.e. >3 points associated with 98% MI, but score of
0 does not rule out STEMI). It should be noted that occlusion
of the left circumflex artery may not be associated with any
ST segment changes on the standard 12-lead ECG, and pur-
suing the diagnosis with posterior lead placement may be
useful, while ST segment depression in V1-3 and abnormal R
waves in V1 may also indicate posterior infarction.
The differential diagnosis for ST segment elevation
includes pericarditis (which is distinguished by more global
ST segment elevation [often concave] across most ECG leads,
often accompanied by PR depression in lead II), stress car-
diomyopathy (i.e. Takotsubo cardiomyopathy) which is
often difficult to differentiate without coronary angiography,
and Brugada Syndrome.
In situations where expertise in ECG interpretation may
not be available, an electronic algorithm for ECG interpreta-
tion (coupled with remote review by an expert) can assist in
diagnosing STEMI. Local/state care pathways should incor-
porate means for allowing expert ECG reading within
10 minutes of first contact, integrated with clinical decision-
making around timely reperfusion. The diagnosis of STEMI
and therefore the decision to initiate reperfusion therapy, does
not depend on results of serial ECGs or troponin testing, or
chest X-ray, although these may assist in prognostication and
determining the extent of myocardial injury.3.1.2. Non-ST-Elevation Acute Coronary
Syndromes (NSTEACS)
The diagnosis of NSTEACS is often more challenging than
STEMI, as is the differentiation of NSTEMI from UA. In such
cases, implementation of the criteria for MI contained within
the Third Universal Definition of MI should be considered
rather than relying on investigational evidence of cardiac
injury alone (i.e. troponin elevation) [53] (Refer to Table 7).
Also to be considered are alternative, and sometimes life-
threatening, non-ACS diagnoses in patients with atypical
features but who demonstrate elevated cardiac biomarkers.
Similarly, among patients with biomarker elevation without
a culprit coronary lesion identified on coronary angiography,
a broad differential diagnosis including Takotsubo cardio-
myopathy, myocarditis, coronary embolism, pulmonary
embolus and coronary spasm should be considered. (See
Table 8)
3.1.3. Type 1 Versus Type 2 Myocardial
Infarction
Among those patients with confirmed MI, applying the diag-
nostic classification in Table 7 may help inform the choice of
potential treatment pathways for ACS. Importantly, though
often clinically challenging, Type 1 MI (i.e. plaque rupture)
must be differentiated from Type 2 MI (oxygen supply-
demand imbalance) in the context of another concurrent
acute illness (e.g. pneumonia or tachyarrhythmia), and
which often presents as NSTEMI. Evidence-based recom-
mendations regarding the use of ACS interventions for
patients with Type 2 MI cannot currently be made. In such
circumstances, clinical assessment should be guided by pre-
event likelihood of prognostically significant CAD and
increased risk of recurrent cardiac events and mortality pro-
portional to the degree of injury, while also weighing the
potential impact of non-cardiac competing risks [110],
including treatment-related harm [111].
3.2. Risk Stratification for Patients with
Confirmed ACS
When clinician intuition of ongoing ischaemic risk is com-
pared directly with risk estimation using risk scores such as
the Global Registry of Acute Cardiac Events (GRACE) and
the Thrombolysis In Myocardial Infarction (TIMI) scores, the
latter show better discrimination and calibration than the
former [28,29,112] (Table 4). For late mortality and recurrent
MI, the GRACE risk score appears to perform better than the
TIMI risk score [113] and may thus be preferred for clinical
decision-making and communication with patients and fam-
ilies. Similarly, risk scores for bleeding risk exist, such as
those derived from the CRUSADE and ACUITY cohort stud-
ies, with CRUSADE being most discriminatory [114,115].
Stratification of ischaemic and bleeding risks may be useful
for guiding initiation of antithrombotic therapies, use and
timing of early invasive management, and transfer to larger
institutions when access to expertise or invasive facilities are
not locally available. For both ischaemic and bleeding risk
Table 10 Markers of increased risk of mortality and recurrent events among patients with confirmed ACS
Risk classification Clinical characteristic
Very High  Haemodynamic instability, heart failure, cardiogenic shock or mechanical complications of MI
 Life-threatening arrhythmias or cardiac arrest
 Recurrent or ongoing ischaemia (i.e. chest pain refractory to medical treatment), or recurrent dynamic
ST-segment and/or T-wave changes, particularly with intermittent ST-segment elevation, de Winter
T-wave changes, or Wellens’ syndrome, or widespread ST-segment elevation in two coronary territories
High  Rise and/or fall in troponin level consistent with MI
 Dynamic ST-segment and/or T-wave changes with or without symptoms
 GRACE Score>140
Intermediate  Diabetes mellitus
 Renal insufficiency (glomerular filtration rate<60mL/min/1.73m2)
 Left ventricular ejection fraction <40%
 Prior revascularisation: Percutaneous coronary intervention or coronary artery bypass grafting
 GRACE score >109 and <140
GRACE = Global Registry of Acute Coronary Events
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care or outcomes is not currently available. Clinical features
associated with the risk of mortality and recurrent ischaemic
events are described in Table 10.
3.2.1. Integrating Stratification of
Ischaemic and Bleeding Risk into
Clinical Decision-Making
Recommendation: The routine use of validated risk strati-
fication tools for ischaemic and bleeding events (e.g.
GRACE score for ischaemic risk or CRUSADE score for
bleeding risk) may assist in patient-centric clinical deci-
sion-making in regards to ACS care. (NHMRC Level of
Evidence (LOE): IIIB; GRADE strength of recommenda-
tion: Weak).
Rationale: Several studies of ACS practice have demon-
strated a mismatch between physician assessment of ischae-
mic and bleeding risks and those derived from validated risk
models [113,116,117]. Over and under estimation of these
risks may contribute to the misapplication of evidence-based
guideline recommendations that are poorly aligned with
individual patient choice or clinical need [118,119]. In partic-
ular, better estimation of bleeding risks may significantly
impact the choice between invasive and non-invasive man-
agement [115] [114]. Nevertheless, it should be noted that
many of these tools have not been validated within Aborigi-
nal and Torres Strait Islander populations and the higher risk
profile of these patients should be recognised. As yet, there
are no prospective randomised trials comparing clinicaljudgement and use of risk scores against clinical judgment
alone in deciding the use of diagnostic and therapeutic inter-
ventions and assessing downstream effects on clinical
outcomes.
Benefits and harms: For the endpoint of mortality or recur-
rent ischaemic events, no estimates of effect can be currently
provided. The likelihood of an increase in adverse outcomes
or the over/under use of therapies is thought to be low, but
remains unproven.
Resources and other considerations: The routine use of risk
tools may provide modest improvements in individualising
care decisions, and may be more relevant to rural settings
where clinical experience may be limited and where deci-
sions regarding transfer to other institutions and its timing
are more frequently encountered. Incorporation of routine
risk scoring into local protocols with the aid of electronic risk
calculators (web/mobile apps) may assist development of
patient-specific clinical care plans and evaluation of the
appropriateness of care within local audit and quality assur-
ance efforts.
Practice Advice
3.2.1.1. Choice of Risk Score. For ischaemic risk, the GRACE
risk score is superior to the TIMI risk score in terms of
discriminating between high- and intermediate- or low-risk
patients. However, estimating risk of recurrent MI or death
for an individual patient depends on local validation [113]. In
regards to bleeding risk scores, the CRUSADE risk score is
preferred, although it has limited validation in the Australian
setting.
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Invasive Management Strategies
in Acute Coronary Syndromes
In patients with confirmed STEMI, the immediate priority is
initiation of an emergency reperfusion strategy to improve
short- and long-term survival and cardiac function.
4.1. Reperfusion for STEMI
4.1.1. Eligibility for Reperfusion
Recommendation: For patients with STEMI presenting
within 12 hours of symptom onset, and in the absence of
advanced age, frailty and co-morbidities that influence the
individual’s overall survival, emergency reperfusion ther-
apy with either primary percutaneous coronary interven-
tion (PCI) or fibrinolytic therapy is recommended.
(NHMRC level of evidence (LOE) 1A; GRADE strength
of recommendation: Strong).
Rationale: The aim of reperfusion therapy is the timely
restoration of coronary flow and myocardial perfusion which
limits the extent of MI and reduces mortality by minimising
the total ischaemic time (i.e. symptom onset to reperfusion)
(Refer to Section 4.1.2). Within current practice, the options for
reperfusion are primary PCI or fibrinolytic therapy. Fibrino-
lytic therapy, compared with control groups, reduces overall
mortality at 35 days with a relative risk of 0.82 (95% CI 0.77-
0.87) based on data from nine trials involving 58,600 patients
[120]. This benefit was greater among those patients with
anterior MI, and those presenting earlier after symptom onset.
The impact on mortality through myocardial salvage is great-
est in the first hour after symptom onset and diminishes with
time, virtually dissipated by 12 hours [121]. An analysis of 22
randomised trials (n=50246) demonstrated an attenuation of
the mortality benefit with fibrinolysis of 1.6 lives per 1,000
patients per hour delay. Within analyses of primary PCI, this
loss of benefit with delay persists, although the attenuation is
less prominent. In the absence of large-scale studies comparing
primary PCI with conservative management, evidence of effi-
cacy is drawn from studies comparing this strategy with in-
hospital fibrinolysis.
Benefits and harm: Refer to Section 4.1.2.
Practice Advice
4.1.1.1. Confirming the Diagnosis of STEMI/LBBB: The
Diagnostic Criteria are Described in Section 3.1.1. In sit-
uations where expertise in ECG interpretation may not be
available, an electronic algorithm for ECG interpretation
(coupled with remote review by an expert) can assist in
diagnosing STEMI. Local care pathways should incorporate
means for allowing expert ECG reading within 10 minutes of
first contact, integrated with clinical decision-making to
enable timely reperfusion.
4.1.1.2. Patients With Advanced Age and Multiple Co-
Morbidities. While age is not a contraindication toreperfusion therapy, decisions regarding reperfusion should
include the patient’s and their family’s or carer’s values and
preferences, and the relative benefits and harms of each
reperfusion strategy (Refer to Section 4.1.2).
4.1.1.3. Patients With Resolved Chest Pain or ECG
Changes. The benefit of reperfusion is not dependent on
the presence of ongoing chest pain and it should be provided
to patients with persistent (>20 minutes) ST elevation/LBBB
within 12 hours, despite resolution of chest pain.
4.1.1.4. Patients With Ongoing Chest Pain and ECG Crite-
ria Presenting After 12 Hours. Persistent ischaemic chest
pain or haemodynamic compromise beyond 12 hours after
symptom onset suggests ongoing ischaemia and potential for
myocardial salvage and reperfusion for these patients should
be considered. Given the lower efficacy and persistent bleed-
ing risks associated with fibrinolysis among patients present-
ing late, reperfusion with primary PCI in this setting is
preferred (Refer to Section 4.1.2.1).
4.1.1.5. Patients with Out-of-Hospital Cardiac Arrest. In
patients with a shockable rhythm and spontaneous return
of circulation associated with persistent ST elevation on the
ECG, reperfusion therapy either with primary PCI or fibrino-
lytic therapy, is recommended. In patients with ST segment
depression, emergency angiography and revascularisation, if
indicated, should be considered.
4.1.2. Choice of Reperfusion Strategy
Recommendation: Primary PCI is preferred for reperfusion
therapy in patients with STEMI if it can be performed
within 90 minutes of first medical contact; otherwise fibri-
nolytic therapy is preferred for those without contra-indi-
cations. (NHMRC level of evidence (LOE) 1A; GRADE
strength of recommendation: Strong).
Rationale: The choice of reperfusion strategy requires con-
sideration of time from symptom onset to first medical
contact, extent of ischaemic myocardium, presence of hae-
modynamic compromise, bleeding risk from fibrinolytic
therapy and expected delays in providing PCI, including
transfer times to PCI-capable hospitals. Meta-analyses of
comparative trials show primary PCI to be superior to fibri-
nolytic therapy in reducing mortality, recurrent MI and
stroke. Compared to fibrinolysis, primary PCI provides an
additional benefit of 1.5–2 lives saved per 100 patients treated
[122] based on a 2003 analysis of 23 trials involving 7,739
patients. Further reductions in rates of recurrent MI and
stroke were also seen. Importantly, these trials predate coro-
nary artery stenting and contemporary peri-procedural
antithrombotic therapy. For patients presenting to non-
PCI-capable centres, withholding fibrinolysis and transfer-
ring in a timely manner to a PCI-capable hospital for primary
PCI, compared to on-site fibrinolysis, was associated with a
reduction in mortality (5.6% vs 6.8%, p<0.02), re-infarction
(2.1% vs 4.7%; p<0.001) and stroke (0.7% vs 1.7%, p=0.0005)
by 30 days in a meta-analysis of 11 trials (n=5741) [123].
Hence, compared with in-hospital fibrinolysis, primary
920 D.P. Chew et al.PCI may provide further reductions in 30-day mortality (0.73
[95% CI 0.62-0.86]) with additional benefits in reducing recur-
rent MI (OR 0.35 [95% CI 0.27-0.45] and stroke risk (OR 0.46
[95% CI 0.30-0.72]) [122].
However, the benefits of PCI over fibrinolysis depend on
context. An observational analysis from the National Regis-
try of MI in the United States demonstrated the relative
benefit of primary PCI over fibrinolysis was lost after a delay
to PCI of 121 minutes [124]. In addition, many trials of pri-
mary PCI (with and without transfer) did not include early
angiography in the fibrinolytic arms. Data from three rela-
tively small trials [125,126] [127] comparing primary PCI
with fibrinolytic therapy as part of a ‘pharmaco-invasive’
strategy using more contemporary antiplatelet therapy and
higher rates [30%] of rescue PCI and early routine angiog-
raphy (6-24 hours) among 3,000 patients showed no differ-
ence in mortality. Furthermore, very early administration of
fibrinolysis in the pre-hospital setting (i.e. pre-hospital fibri-
nolysis) may confer superior outcomes to PCI, especially
among patients presenting within two hours of symptom
onset [128].
Benefits and harms: Estimates of the absolute reduction in
mortality by 30 days with fibrinolysis is 4% (NNTB 25) with a
further 1.5-2% reduction associated with primary PCI (NNTB
50-63). This relative benefit is diminished with pre-hospital
fibrinolysis and when delay to PCI is >2 hours. Fibrinolysis is
associated with a 2% risk of stroke (NNTH 50) [122]. Com-
pared with fibrinolysis, primary PCI is associated with a 1%
lower risk of stroke (NNTB 100).
Practice Advice
4.1.2.1. Clinical Circumstances where the Administration
of Fibrinolytic Therapy (Assuming ‘Door-to-Needle’ Time
30 Minutes) Should be Considered the Default Reperfu-
sion Strategy
 Patients presenting to ED or suitably trained pre-hospital
paramedic teams within 60 minutes of symptom onset.
 Patients presenting within 60-120 minutes after symptom
onset in whom the expected delay to first device time is
>90 minutes.
 Unacceptable delays in cardiac catheter laboratory activa-
tion for primary PCI.
 Patient factors likely to impede successful performance of
primary PCI: e.g. severe contrast allergy or poor vascular
access.
4.1.2.2. Contra-Indications to Administration of Fibrino-
lytic Therapy (Consider Expert Consultation)
 BP>180/110 mmHg
 Recent trauma/surgery
 Gastrointestinal or genitourinary bleeding within previous
2–4 weeks
 Stroke/TIA within 12 months
 Prior Intracranial haemorrhage at any time
 Current anticoagulation or bleeding diathesis (relative
contraindication with warfarin)4.1.2.3. Clinical Circumstances where Primary PCI may be
the Preferred Reperfusion Strategy due to Reduced Efficacy
or Increased Bleeding Risk with Fibrinolytic Therapy
 Longer patient delay from symptom onset (2-4 hours),
primary PCI is preferred if delay between first medical
contact and first device time is expected to be <120
minutes.
 Late presentation after symptom onset (>4 hours), primary
PCI is preferred due to lower efficacy with fibrinolytic
therapy.
 Patients with haemodynamic compromise or cardiogenic
shock, with the option of urgent coronary artery bypass
grafting (CABG).
 Increased bleeding risk: among the elderly, patients with
significant co-morbidity.
4.1.2.4. Strategies for Reducing the Time to Reperfusion
Therapy. Coordinated protocols with planned decision-mak-
ing that incorporates ambulance services and paramedics,
first responder primary care physicians, emergency and car-
diology departments are critical for achieving acceptable
reperfusion times. While strategies need to be tailored to
the local community and their distribution of emergency
services, strategies that effectively shorten the time to reper-
fusion include: developing hospital networks with pre-deter-
mined management pathways for reperfusion; pre-hospital
ECG and single-call catheter laboratory activation; pre-hospi-
tal fibrinolysis by suitably trained clinicians (e.g. paramedics),
the bypassing, where appropriate, of non-PCI capable hospi-
tals; and bypassing the ED on arrival in PCI centres. Further-
more, an established capability for timely expert consultation
for complex clinical scenarios is highly desirable. In the con-
text of a system-based approach to reperfusion, the capacity
for continuous audit and feedback is also recommended.
4.1.3. Practical Considerations Regarding
Administration of Fibrinolytic Therapy
4.1.3.1. Choice of Fibrinolytic
Currently available fibrinolytics include: tenecteplase
(weight adjusted [30-50 mg] IV bolus); reteplase 10 units
IV followed by 10 units IV, 30 minutes later; alteplase (weight
adjusted accelerated bolus and infusion regimen); and strep-
tokinase 1.5 million units IV infusion over 30–60 minutes.
(Note that streptokinase is associated with a higher rate of
hypotension and intracerebral haemorrhage and, due to a
high prevalence of streptococcal antibodies, should not be
used for Aboriginal and Torres Strait Islander patients). A
fibrinolytic agent that can be given as a bolus dose such as
tenecteplase is advisable for ease of administration, especially
in the pre-hospital setting. In patients aged 75 years, admin-
istration of half the standard dose of tenecteplase should be
considered in reducing risk of intracranial bleeding [127].
4.1.3.2. Adjunctive Pharmacotherapy
 Antithrombin therapy: Enoxaparin is recommended over
unfractionated heparin (refer to Section 5.3.1.2) [129].
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dogrel (300 mg loading dose and 75 mg per day) is rec-
ommended at the time of fibrinolytic therapy. Currently,
the safety and efficacy of ticagrelor or prasugrel has not
been studied in conjunction with fibrinolysis (i.e. within
24 hours of fibrinolytic therapy).
4.1.4. Technical Aspects of Primary PCI
4.1.4.1. Mode of Arterial Access
Radial access is preferred over femoral access, largely due to
reduced local bleeding, unless there are compelling reasons
to use femoral access (such as imminent deployment of an
intra-aortic balloon pump (IABP) [130] [131].
4.1.4.2. Peri-Procedural Pharmacotherapy
Unfractionated heparin (UFH) or enoxaparin is indicated in
patients undergoing primary PCI. Similarly, substantial data
supports the use of glycoprotein IIb/IIIa inhibitors, or alter-
natively, bivalirudin in primary PCI (refer to Section 5).
4.1.4.3. Aspiration Thrombectomy of Infarct-Related
Artery (IRA)
Meta-analysis of several studies of this procedure has shown
no reduction in mortality and a small increased risk of stroke
with the routine use of thrombo-aspiration of the IRA [132].
Thrombus aspiration can be considered when large throm-
bus burden impairs achievement of a satisfactory PCI result.
4.1.4.4. IABP for Ongoing Cardiogenic Shock
Routine IABP use in cardiogenic shock complicating STEMI
treated by primary PCI has not been shown to reduce 30-day
or 6-month mortality and should be avoided.
4.1.4.5. Complete Revascularisation at the Time of
Primary PCI
In several small studies, complete revascularisation of all
stenosed coronary arteries in patients with multi-vessel dis-
ease at the time of primary PCI, rather than IRA stenosis
alone, may lessen onset of recurrent ischaemia, although the
number of objective late cardiovascular events in these trials
was small [133,134].
4.2. Ongoing Management of
Fibrinolytic-Treated Patients
4.2.1. Transfer and Subsequent
Angiography Post Fibrinolysis
(a) Recommendation: Among patients treated with fibri-
nolytic therapy who are not in a PCI-capable hospital,
early or immediate transfer to a PCI-capable hospital
for angiography, and PCI if indicated, within 24 hours
is recommended. (NHMRC level of evidence (LOE)
IIA; GRADE strength of recommendation: Weak).
(b) Recommendation: Among patients treated with fibri-
nolytic therapy, for those with 50% ST recovery at 60–
90 minutes, and/or with haemodynamic instability,
immediate transfer for angiography with a view torescue angioplasty is recommended. (NHMRC level
of evidence (LOE) 1B; GRADE strength of recommen-
dation: Strong).
Rationale: Among patients receiving fibrinolysis but who
were not in a PCI-capable hospital, immediate or early trans-
fer for angiography, and PCI if indicated, within 24 hours
after fibrinolytic therapy is associated with reduced ischae-
mic events [135] [136]. In a meta-analysis of seven trials of
2,961 patients, no difference in mortality was observed. There
was a relative risk reduction in recurrent MI and recurrent
ischaemia, (OR 0.55, 95% CI 0.36-0.82) and (OR 0.25, 95%, CI
0.13-0.49). The benefit in recurrent MI persisted to 6-12
months, with no increase in bleeding or stroke risk. However,
the benefits may be confounded by ascertainment bias
among those having early angiography/PCI [137].
Among fibrinolytic-treated patients who do not achieve
50% reduction in ST segment elevation at 60–90 minutes after
commencement of fibrinolytic therapy, and/or have persis-
tent haemodynamic instability, immediate transfer for angi-
ography with a view to rescue angioplasty is associated with
a non-significant reduction in mortality (RR 0.69 [95% CI
0.46-1.05), but a significant reduction in re-infarction (RR
0.58 [95% CI 0.35-0.97) [138]. However, stroke was increased
five-fold (RR 4.98, 95% CI 1.10-22.5), albeit in an era with
predominant femoral access and a significant proportion of
patients receiving streptokinase.
Benefits and harms: For the endpoint of recurrent MI, routine
early transfer and angiography for patients receiving effec-
tive fibrinolysis is estimated to provide a 2.8% absolute
reduction in recurrent MI by 6-12 months (NNTB 35) without
any increase in bleeding events.
Current data for rescue PCI demonstrates a reduction in
recurrent MI but no significant reduction in mortality. Local
estimates of re-infarction rates among patients with failed
reperfusion are uncertain. While no estimates of absolute
benefit are provided, event rates in untreated patients are
high.
Resources and other considerations: Systems of care should be
developed to achieve these transfer timelines (refer to
Figure 4) [139]. Urgent consultation and transfer to centres
with higher clinical expertise and interventional facilities
should be considered. Systems of care should be developed
to provide advice and enable, when appropriate, immediate
or early transfer for angiography among fibrinolytic-treated
patients who are not in a PCI-capable hospital.
Practice Advice
4.2.1.1. Detection of Failed Reperfusion. Among fibrino-
lytic-treated patients, failed reperfusion is defined as 50%
ST recovery on an ECG performed at 60-90 minutes. Also
ongoing haemodynamic instability, and ongoing ischaemic
chest pain are indications for immediate angiography
4.3. Early Invasive Management for
NSTEACS
The routine provision of early coronary angiography with
subsequent revascularisation (i.e. PCI or CABG as indicated)
Figure 4 Decision-making and timing considerations in reperfusion for STEMI. (Adapted from [212].)
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vational studies and systematic reviews spanning two dec-
ades in the context of evolving patient selection criteria,
adjunctive pharmacotherapies, and interventional practices.
Overall, a net benefit in terms of reduction in late composite
endpoints of death, recurrent MI and re-hospitalisation for
ischaemia have been observed. However, no reduction in
mortality alone has been observed. Patient preferences and
goals of therapy, ischaemic and bleeding risk, impacts of
other major co-morbidities, and the patient burden of travel
from rural and remote settings to tertiary centres all need to
be considered in decision-making. The following recommen-
dations allow for latitude according to individual patient
circumstances.4.3.1. Routine Versus Selective Invasive
Management for NSTEACS
(a) Recommendation: Among high- and very high-risk
patients with NSTEACS (except Type 2 MI), a strategy of
angiography with coronary revascularisation (PCI or
CABG) where appropriate is recommended. (NHMRC
Level of Evidence (LOE): IA; GRADE strength of recom-
mendation: Strong).
(b) Recommendation: Patients with NSTEACS who have
no recurrent symptoms and no risk criteria are considered
at low risk of ischaemic events, and can be managed with a
selective invasive strategy guided by provocative testing
for inducible ischaemia (NHMRC Level of Evidence (LOE):
IA, GRADE strength of recommendation: Strong).
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have examined invasive management of NSTEACS [140–
142]. In a Cochrane review of five randomised trials (7,818
participants) performed in the modern stent era, all-cause
mortality during initial hospitalisation was associated with
a non-significant early hazard with an invasive strategy (RR
1.59, 95% CI 0.96-2.64) with no difference seen on longer-
term follow-up (RR 0.90, 95% CI 0.78-1.08). Rates of recur-
rent MI assessed at 6-12 months (five trials) and 3-5 years
(three trials) were significantly decreased by an invasive
strategy (RR 0.73, 95% CI 0.62-0.86; and RR 0.78, 95% CI
0.67-0.92 respectively). The incidence of early (< 4 months)
and intermediate (6-12 months) refractory angina were also
significantly decreased by an invasive strategy (RR 0.47,
95% CI 0.32-0.68; and RR 0.67, 95% CI 0.55-0.83 respec-
tively), as were rates of early and intermediate re-hospital-
isation for recurrent ACS (RR 0.60, 95% CI 0.41-0.88; and RR
0.67, 95% CI 0.61-0.74 respectively). The invasive strategy
was associated with a two-fold increase in risk of peri-
procedural MI (as variably defined) and an increase in risk
of bleeding (RR 1.71, 95% CI 1.27-2.31) with no increased
risk of stroke [143].
In another meta-analysis, a routine invasive strategy
reduced the composite end-point of death and MI although
this benefit was confined to biomarker-positive patients (OR
0.68, 95% CI 0.56-0.82) [144]. An individual patient data
meta-analysis of three randomised trials with long-term
follow-up out to five years reported a lower risk of cardio-
vascular death or MI in favour of a routine invasive strategy
(14.7% vs 17.9%; HR 0.81, 95% CI 0.71-0.93), with benefit
increasing according to patient risk (absolute risk reduction
of 2.0%, 3.8% and 11.1% among low-, intermediate- and
high-risk patients respectively) [142]. The most comprehen-
sive meta-analysis includes 9,400 patients randomised in
nine trials conducted from 1999 to 2012 [143]. Overall, the
composite endpoint of death or recurrent MI was lower with
routine early invasive management compared with selec-
tive invasive management (OR 0.85, 95% CI 0.76-0.95,
I2=50.4%). For the individual component end-points, great-
est benefits are observed for recurrent MI (OR 0.75, 95% CI
0.66-0.87, p<0.0001) and re-hospitalisation for ischaemia
(OR 0.71, 95% CI 0.55-0.90). No reductions were seen in
overall mortality (OR 0.95, 95% CI 0.83-1.09). The high level
of between-study heterogeneity in these meta-analyses
reflect differences in adjunctive pharmacology, patient risk
profiles and rates of invasive management between routine
and selective arms.
Benefits and harms: When considering a routine early inva-
sive approach, the relative benefits and harms should be
weighed within the context of patient preferences and co-
morbidities and competing clinical risks. A routine invasive
approach to the management of NSTEACS patients is esti-
mated to reduce the absolute rates of the combined end-point
of death, recurrent MI and cardiovascular re-hospitalisation
at 12 months by approximately 4.9% (NNTB 22), though the
majority of this benefit is in non-fatal events.
Resources and Other Considerations:Cost-effectiveness: The cost-effectiveness of this approach in
those with substantial co-morbidities or in the setting of rural
or remote patients has not been studied.
Concomitant therapies: Implementation of an early invasive
strategy requires optimal use of concurrent parenteral anti-
coagulation (e.g. unfractionated heparin (UFH), enoxaparin,
bivalirudin) (refer to Section 5.3). Aspirin is advocated in
all patients with no allergy to this agent. Initiation of a P2Y12
inhibitor (i.e. clopidogrel and ticagrelor) at the time of
diagnosis is supported by evidence while benefits of initia-
tion prior to coronary angiography in patients undergoing
an early invasive approach remain uncertain (refer to
Section 5.2.2.2).
Procedural considerations: The use of radial access for coro-
nary angiography should be considered, particularly where
bleeding risk is increased. The mode of revascularisation (i.
e. PCI vs CABG) should consider anatomical disease bur-
den, as well as clinical characteristics and patient prefer-
ences that may be best served with a heart team approach.
The use of drug-eluting stents versus bare metal stenting
depends on lesion and patient characteristics, including the
need for long-term oral anticoagulation. Emerging data
suggest benefits in reducing non-fatal MI associated with
more complete revascularisation (i.e. the revascularisation
of non-culprit coronary lesions) within the first 48 hours of
presentation, but definitive evidence about effects on mor-
tality are awaited. The value of fractional flow reserve
(FFR)-guided PCI, or of complete revascularisation in the
setting of FFR-guided PCI, has not been subject to random-
ised trials and hence no recommendations are possible
currently.
Practice Advice
4.3.1.1. Mode of Revascularisation. Overall, patients suffer-
ing NSTEACS require CABG in approximately 10% of cases.
The factors to be considered in deciding between PCI and
CABG in NSTEACS do not differ from those among patients
presenting electively. Patient comorbidities, fitness for major
surgery, and coronary anatomy are the main determinants.
Urgent revascularisation with CABG may be indicated for
failed PCI, cardiogenic shock and mechanical defects result-
ing from MI (e.g. septal, papillary muscle, or free-wall rup-
ture). Operative outcomes in emergency settings are inferior
to those of elective cases, and timing needs to take the
antiplatelet strategy into account. A combined heart team
approach may provide the best consensus decision about the
care of each individual patient.
4.3.1.2. The Elderly Patient. Chronological age, in isolation,
should not determine eligibility for routine invasive strategy.
Meta-analyses indicate older patients experience more
events and derive greater absolute reductions in recurrent
ischaemic events from the routine invasive approach,
although few patients aged >80 years have been enrolled
in trials, limiting the quality of evidence in the very elderly
[145,146]. Elderly patients should be considered for an inva-
sive strategy after careful evaluation of potential harms and
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quality of life, frailty, and patient values and preferences.
4.3.1.3. Patients With Diabetes. Patients with diabetes are at
increased risk of future fatal and non-fatal cardiac events
following NSTEACS. Studies to date have been too small to
evaluate effects of a routine invasive strategy, although there
is potential for benefit given the high prevalence of multi-
vessel CAD and benefits associated with CABG over PCI in
such patients.
4.3.1.4. Patients With Chronic Kidney Disease (CKD).
There are limited data regarding relative harms and benefits
of a routine invasive strategy among patients with moderate
to severe CKD despite their increased risk of death and
recurrent cardiac events. Adequate pre-hydration with nor-
mal saline and minimal volumes of low- or iso-osmolar
contrast media are recommended when employing an inva-
sive strategy. The evidence for use of N-acetyl cysteine is
heterogeneous and therefore precludes definitive
recommendations.
4.3.1.5. Patients With Heart Failure. Reduced left ventricu-
lar systolic function in patients with NSTEACs is associated
with an increase in late mortality, recurrent MI and re-hos-
pitalisation. No randomised trials have assessed effects of a
routine invasive strategy in such patients, although trials of
CABG in patients with heart failure outside the context of
ACS have shown modest benefit [147].
4.3.1.6. Rural and Remote Patients. Decisions regarding
transfer of patients to PCI-capable facilities for urgent angi-
ography in the absence of recurrent ischaemia should be
based on estimated individualised risks for future events,
need for other non-invasive services and informed patient
preferences.
4.3.1.7. Invasive Management for Type 2 MI (refer to 3.1.3,
and to Table 7). Type 2 MI remains a challenging diagnosis
and no trials have examined the benefits of a routine invasive
strategy in patients with Type 2 MI. In the absence of any
trial evidence, angiography with a view to revascularisation
may be considered if there is ongoing ischaemia or haemo-
dynamic compromise despite adequate treatment of the
underlying acute medical problem which provoked the
Type 2 MI.
4.3.2. Optimal Timing of Invasive
Management for Patients Undergoing
Invasive Strategy
(a) Recommendation: Very high-risk patients: Among
patients with NSTEACS with very high-risk criteria (ongo-
ing ischaemia, haemodynamic compromise, arrhythmias,
mechanical complications of MI, acute heart failure, recur-
rent dynamic or widespread ST-segment and/or T-wave
changes on ECG), an immediate invasive strategy is rec-
ommended (i.e. within two hours of admission). (NHMRCLevel of Evidence (LOE): IIC; GRADE strength of recom-
mendation: Strong).
(b) Recommendation: High-risk patients: In the absence
of very high-risk criteria, for patients with NSTEACS with
high-risk criteria (GRACE score >140, dynamic ST-segment
and/or T-wave changes on ECG, or rise and/or fall in tro-
ponin compatible with MI) an early invasive strategy is
recommended (i.e. within 24 hours of admission),
(NHMRC Level of Evidence (LOE): IC, GRADE strength
of recommendation: Weak)
(c) Recommendation: Intermediate-risk patients: In the
absence of high-risk criteria, for patients with NSTEACS
with intermediate-risk criteria (such as recurrent symptoms
or substantial inducible ischaemia on provocative testing),
an invasive strategy is recommended (i.e. within 72 hours
of admission). (NHMRC Level of Evidence (LOE): IIC,
GRADE strength of recommendation: Weak)
Rationale: In the most comprehensive meta-analysis exam-
ining optimal timing of angiography among NSTEACS
patients in whom use of invasive management had been
decided, (5,370 patients within seven randomised trials;
77,499 patients within four observational studies), early or
delayed intervention was defined as treatment within, or
beyond, approximately 20 hours of presentation [148,149].
Overall, there was no reduction in mortality, recurrent MI
or major bleeding events. Only one study (TIMACS) had
sufficient power to assess the subgroup interaction (n=961)
between timing of intervention and baseline patient ischae-
mic risk. It found a reduction in death, MI and stroke
at six months associated with early (within 24 hours) versus
delayed (median time 50 hours) intervention (13.9% vs.
21.0%, p = 0.005) among patients with a GRACE risk score
>140 [150], with no increase in major bleeding.
Benefits and harms: Routine use of an early (within 24 hours)
invasive strategy in all patients with NSTEACS, in the
absence of considering individual risk, is unlikely to reduce
mortality, recurrent MI or bleeding. On the basis of current
data, there is little or no clinical harm or benefit associated
with the use of a routine invasive strategy within 24 hours of
presentation in patients who do not demonstrate very high or
high-risk criteria.
Resources and other considerations: The current recommen-
dations assume appropriate initiation of adjunctive phar-
macotherapies. The cost-effectiveness of an invasive
approach in patients with co-morbidities or in rural or
remote settings has not been adequately delineated. Never-
theless, early angiography is associated with reduced hos-
pital length of stay.
Practice Advice
4.3.2.1. Very High-Risk Patients. In patients, in whom the
decision has been made to pursue invasive management,
urgent access to coronary angiography (within two hours),
which may require inter-hospital transfer, is recommended.
4.3.2.2. High-Risk Patients (see Table 10). Such patients
should undergo early invasive intervention (within 24 hours).
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MI or cardiac death among patients with ischaemia on
provocative testing remains low over the short term (i.e.
within 30 days). This risk is influenced by the extent of
LV ischaemia, with an ischaemic burden affecting >10% ofthe left ventricle being defined as a critical threshold.
Consideration of the timing of inpatient (within 72 hours)
versus outpatient angiography should consider this ischae-
mic burden in addition to other clinical and logistical
factors.
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Coronary Syndromes
5.1. Acute Anti-Ischaemic Therapies
Within the acute management of patients with ongoing
ischaemia, oxygen therapy, nitrates, beta blockers and opioid
analgesia may have a role in offering short-term symptom
relief. These therapies have not been shown to reduce the
incidence of recurrent MI or death and therefore should not
be considered as an alternative to early invasive management
among patients where revascularisation is considered clini-
cally appropriate. In the absence of adequate data document-
ing an impact on clinical outcomes, discussion of these agents
is offered as practice advice.
Practice Advice
5.1.1.1. Oxygen Supplementation: Refer to Section 2.3.1.1.
5.1.1.2. Nitrates. By providing vasodilatation and lowering
blood pressure, either sublingual, transdermal or IV nitrates
are effective in controlling the symptoms of ischaemia. Intra-
venous administration is more effective but requires closer
blood pressure monitoring. These agents are contraindicated
in patients who have recently taken type 5 phosphodiesterase
inhibitors due to the risk of profound hypotension.
5.1.1.3. Beta Blockers. Through the inhibition of catechol-
amine effects, beta blockers reduce ischaemia by decreasing
myocardial oxygen demand. Evidence of benefit in reducing
mortality with these agents is observed within large-scale
meta-analyses of studies pre-dating current revascularisation
and pharmacologic practices. A more recent meta-analysis
[151] which stratified studies by reperfusion/revascularisa-
tion practice has suggested relative reductions in mortality of
14% in the pre-reperfusion era (incident rate ratio [IRR] 0.86,
95% CI 0.79-0.94) but not in the current era (IRR 0.98, 95% CI
0.92-1.05), interaction p-value: 0.02. Within contemporary
trials, beta blockers are associated with a significant reduc-
tion in recurrent MI (IRR 0.72, 95% CI 0.62-0.83) and angina
(IRR 0.80, 95% CI 0.65-0.98), but a significant increase in heart
failure (IRR 1.10, 95% CI 1.05-1.16) and cardiogenic shock
(IRR 1.29, 95% CI 1.18-1.40). Caution in using beta blockers
should be exercised when LV function is known to be low or
there is evidence of haemodynamic compromise, conduction
abnormalities or inferior infarction.
5.1.1.4. Opioid Analgesia. Among patients with ongoing
chest pain despite other anti-ischaemic therapies, the use
of opioid analgesia (e.g. morphine, or fentanyl [not pethi-
dine]) may be considered. However, the potential for these
agents to slow gastric emptying and delay the absorption of
other oral ACS therapies, in particular oral P2Y12 inhibitors,
should be considered when planning peri-procedural anti-
platelet therapies.
5.2. Antiplatelet Therapy
Several parenteral and oral antiplatelet therapies have well
established efficacy in patients with ACS. However, evidencecontinues to evolve regarding the optimal timing of initiation
in association with invasive management, which combina-
tions of agents are best for specific patients, and their effects
when used concurrently with anticoagulants.
5.2.1. Aspirin
Recommendation: Aspirin 300 mg orally (dissolved or
chewed) initially followed by 100-150 mg/day is recom-
mended for all patients with ACS in the absence of hyper-
sensitivity. (NHMRC Level of Evidence (LOE): IA; GRADE
strength of recommendation: Strong).
Rationale: Aspirin is an inhibitor of the cycloxygenase
pathway, and inhibits the collagen activation of platelets
by thromboxane A2. Its use is supported by a large collabo-
rative meta-analysis of 15 randomised trials conducted
before 1997 involving 19,302 patients [152]. Compared with
placebo, aspirin reduces risk of serious vascular events (vas-
cular death, MI and stroke) with an OR of 0.70 (95% CI 0.64-
0.77). The risk of haemorrhagic stroke is increased while that
of ischaemic stroke decreased, giving an overall reduction in
all-stroke risk (OR 0.62, 95% CI 0.33-0.91). More recently,
high-dose aspirin was compared with low-dose aspirin
among 26,086 patients which showed no significant differ-
ence in ischaemic or bleeding events between groups [153].
The incremental effect of aspirin among patients treated with
potent P2Y12 inhibition is not known and is currently under
investigation.
Benefits and harms: Based on contemporary event rates,
aspirin is estimated to reduce the incidence of death or
recurrent MI and stroke at 12 months by 5 percentage points
(NNTB 21) without a discernible increase in bleeding. These
effect estimates predate co-administration of contemporary
antiplatelet therapy.
Resources and other considerations: Considering the favour-
able harm-benefit profile, ease of administration and very
low cost, aspirin use should be included in all management
protocols for ACS, including those for pre-hospital care.
Practice Advice
5.2.1.1. High-Risk Patients. While definitive data are lack-
ing, the absolute benefits for aspirin are likely to be greater
among patients at high risk for recurrent ischaemic events
such as the elderly, diabetic patients and those with renal
impairment. Enteric-coated aspirin preparations and concur-
rent prescription of proton-pump inhibitors (PPI) should be
considered in patients at increased risk of upper gastrointes-
tinal bleeding, especially when aspirin is prescribed in com-
bination with other antiplatelet agents and anticoagulants.
The use of enteric-coated preparations should be avoided at
the time of emergency presentations due to delayed gastro-
intestinal (GI) absorption.
5.2.2. P2Y12 Inhibition
Recommendation: Among patients with confirmed ACS at
intermediate to very high risk of recurrent ischaemic
events, use of a P2Y12 inhibitor (ticagrelor 180 mg orally,
then 90 mg twice a day; or prasugrel 60 mg orally then
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per day) is recommended in addition to aspirin (ticagrelor
or prasugrel preferred: See practice advice). (NHMRC
Level of Evidence (LOE): IA; GRADE strength of recom-
mendation: Strong).
Rationale: Platelet inhibition through the antagonism of the
P2Y12 receptor has a key role in reducing recurrent ischaemic
events across the spectrum of ACS patients. While the effi-
cacy of clopidogrel (300 mg oral bolus and 75 mg daily) plus
aspirin (i.e. dual antiplatelet therapy [DAPT]) over aspirin
alone in ACS patients is now well established, newer more
potent P2Y12 inhibitors with superior efficacy are currently
available [154] [155]. Among ACS patients undergoing PCI,
prasugrel (60 mg oral bolus and 10 mg daily) was more
effective than standard dose clopidogrel when added to
aspirin, for reducing the composite endpoint of death, recur-
rent MI and stroke, but was associated with an increase in
bleeding events, especially among patients requiring CABG.
In patients over 75 years age or of low body weight (<60 kg)
or prior cerebrovascular disease, prasugrel was associated
with more harm than benefit when compared with clopiod-
grel. Among intermediate- to very-high-risk ACS patients
subjected to either an invasive or conservative strategy,
ticagrelor (180 mg oral bolus and 90 mg twice daily) was
more efficacious than clopidogrel in reducing ischaemic
events among patients treated with concurrent aspirin [156].
Within this study, a small absolute, but statistically significant
reduction of cardiovascular mortality was also observed,
although at the expense of increased non-CABG related bleed-
ing risk.
Summary of the P2Y12 trials demonstrates that, compared
with placebo, clopidogrel is associated with a relative reduc-
tion in death, recurrent MI or stroke (OR 0.80, 95% CI 0.72-
0.90, p<0.001), and a relative increase in major bleeding (OR
1.38, 95% CI 1.13-1.67) [154]. When compared with clopidog-
rel, prasugrel is associated with a relative reduction in death,
recurrent MI or stroke by 12 months (OR 0.81, 95% CI 0.73-
0.91), and a relative increase in major bleeding (OR 1.32, 95%
CI 1.03-1.68) [157]. Further, when compared with clopidog-
rel, ticagrelor is associated with a relative reduction in death,
recurrent MI or stroke (OR 0.84, 95% CI 0.77-0.92), and a
relative increase in major bleeding (OR 1.25, 95% CI 1.03-1.53)
[156] when using similar definitions.
Benefits and harms: The addition of ticagrelor to aspirin
among ACS patients undergoing PCI is expected to reduce
the absolute rate of death, recurrent MI or stroke over
12 months by 5.3% (NNTB 19) but increase the absolute rate
of in-hospital major bleeding events by 1% (NNTH 100).
Adding prasugrel to aspirin among ACS patients undergo-
ing PCI is expected to reduce the absolute rate of death,
recurrent MI or stroke over 12 months by 5.7% (NNTB 18)
but increase the absolute rate of in-hospital major bleeding
events by 1.2% (NNTH 86). The addition of clopidogrel to
aspirin is expected to reduce the rate of death, recurrent MI
and stroke by 3.2 percentage points over 12 months (NNTB
31), but increase in-hospital major bleeding by 0.5 percentage
points (NNTH 183).Resources and other considerations: The incremental cost
effectiveness of use of the newer P2Y12 agents in place of
clopidogrel has not been evaluated.
Practice Advice
5.2.2.1. Choice Between P2Y12 Inhibitors. Given superior
efficacy ticagrelor and prasugrel are the preferred first line
P2Y12 inhibitors. Use of ticagrelor is advised among a broad
spectrum of ACS patients with STEMI or NSTEACS who are
at intermediate to high risk of an ischaemic event in the
absence of atrioventricular (AV) conduction disorders (sec-
ond and third degree AV block) and asthma/chronic
obstructive pulmonary disease (COPD). Prasugrel may be
considered in patients who have not received a P2Y12 antag-
onist in whom PCI is planned, but should not be used for
patients >75 years of age, of low body weight (< 60 kg), or
with a history of transient ischaemic attacks (TIAs) or stroke
disease. Use of either prasugrel or ticagrelor, rather than
clopidogrel is also recommended in patients with recurrent
events on clopidogrel or who have experienced stent throm-
bosis. Clopidogrel is recommended for patients who cannot
receive ticagrelor or prasugrel, as an adjunctive agent with
fibrinolyisis or for those requiring oral anticoagulation.
(Refer to relevant prescriber information documentation).
5.2.2.2. Timing of P2Y12 Initiation. In a trial of the optimal
timing of initiation for P2Y12 inhibition in association with
PCI), earlier ‘pre-treatment’ with prasugrel 30 mg at the
time of diagnosis (before angiography) compared to 60 mg
at the time of PCI following angiography did not reduce
ischaemic events, but did increase bleeding events, espe-
cially in those requiring CABG [158]. A lack of treatment
efficacy was also seen with pre-hospital initiation of tica-
grelor compared with initiation in the catheterisation lab-
oratory in STEMI patients [159]. Based on these limited
data:
 Ticagrelor or clopidogrel should be commenced soon after
diagnosis but due consideration should be given to ischae-
mic and bleeding risk, the likelihood of needing CABG
(more likely in patients with extensive ECG changes, ongo-
ing ischaemia or haemodynamic instability) and the delay
to angiography.
 Prasugrel should be commenced immediately following
diagnosis among patients undergoing primary PCI for
STEMI, or after the coronary anatomy is known among
those undergoing urgent PCI. Initiation of prasugrel prior
to coronary angiography outside the context of primary
PCI is not recommended.
5.2.2.3. Duration of P2Y12 Inhibition in DAPT. Based on
the initial P2Y12 inhibitor trials, the standard duration of
DAPT has been 12 months following the index event. How-
ever, more recent studies and a meta-analysis of prolonged
therapy focussing on patients with prior MI demonstrated a
relative reduction in cardiovascular death (RR 0.85, 95% CI
0.74-0.98), and recurrent MI (RR 0.70, 95% CI 0.55-0.88),
but with an increase in bleeding events (RR 1.73, 95%
Figure 5 Considerations for dual antiplatelet therapy (DAPT) in patients with ACS [163].
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overall mortality. The risk of recurrent ischaemic events must
be carefully weighed against the risk of bleeding events using
risk scoring methods (e.g. possible tools include the DAPT
Score) [160]. Extending P2Y12 inhibition up to three years
with either clopidogrel and ticagrelor [161] may be consid-
ered in patients at high-risk of recurrent ischaemic events
with low bleeding risk. (Note: troponin-positive ACS
identifies patients at increased risk and therefore likely to
receive greater benefit in trials of prolonged DAPT following
both bare metal stents (BMS) and drug eluting stents
(DES)[162].) Conversely, among patients with a high bleed-
ing risk and low risk for recurrent ischaemic events, a
shorter duration of treatment (e.g. six months) may be con-
sidered. Based on the most recent systematic review of alltrials and meta-analyses performed up to the time of release
of these guidelines [163], Figure 5 provides guidance in
regards to a comprehensive evaluation of ischaemic and
bleeding risk in deciding duration of DAPT following PCI
using DES.
5.2.2.4. Discontinuation of P2Y12 Inhibition Prior to Car-
diac and Non-Cardiac Surgery. The increased risk of ischae-
mic events and stent thrombosis should be weighed against
the reduced risk of bleeding events when considering dis-
continuation of P2Y12 inhibition in individual patients.
Discussion between physician and surgeon should be under-
taken. If these agents are to be discontinued, ticagrelor and
clopidogrel should be suspended for five days, and prasugrel
for seven days prior to surgery. Platelet function testing may
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menced as soon as feasible after the surgery.
5.2.2.5. P2Y12 Dosing Among Patients With CKD. Dose
adjustment of the P2Y12 inhibitors for patients with stage 4
or less CKD is not required. In stage 5 CKD, ticagrelor and
prasugrel are not recommended.
5.2.2.6. Genetic or Platelet Function Testing for Clopidog-
rel. While differences in platelet inhibition achieved by clo-
pidogrel has been observed with various genetic
polymorphisms, in association with higher rates of ischaemic
events, using genetic testing to guide the dosing of clopidog-
rel or choice of P2Y12 inhibitor has not been adequately
examined and cannot be recommended. Similarly, reduced
responsiveness to clopidogrel based on platelet function
assays has been correlated with an increased recurrent
ischaemic event rate, but trials of platelet function testing
to guide clopidogrel dosing or choice of P2Y12 inhibitor have
not demonstrated improved outcomes and routine use of
platelet function testing is not recommended.
5.2.2.7. Combination of P2Y12 Inhibition with Long-Term
Anticoagulation. Among patients with an indication for oral
anticoagulation (OAC), a careful assessment of thrombotic
and bleeding risks is required using CHA2DS2VASC and
HAS-BLED scores respectively. The following advice is
based on consensus opinion.
Acute management: For patients treated with either vitamin
K antagonists (VKAs) or non-VKA oral anticoagulants
(NOACs), indication and timing of angiography should be
determined as described in Section 4.3. In patients at very
high risk of recurrent ischaemic events, patients should pro-
ceed to angiography without interruption of VKA or NOAC,
with radial access preferred. The initiation of P2Y12 inhibition
prior to angiography is not recommended. Low-dose intra-
procedural heparin (e.g. 2000 units) is suggested in patients
treated with NOACs regardless of timing of the last dose. For
patients not at very high risk of recurrent ischaemic events,
delay (refer to Section 4.3.2.3 and 5.3.1.4) in providing inva-
sive management may allow for suspension of oral antico-
agulation resulting in some return of coagulation function.
Note, newer generation drug eluting stents appear to be
associated with a lower rate of stent thrombosis and may
be preferred when planning the duration of combination
antiplatelet and OAC therapy.
Long-term management: In patients with a strong long-term
indication for anticoagulation (i.e. mechanical heart valves,
atrial fibrillation [AF] with CHA2DS2VASC score 2), the
anticoagulant should be continued at a reduced dose (i.e.
VKA, Target INR 2.0-2.5, apixaban 2.5 mg BD, rivaroxaban
15 mg daily, dabigatran 110 mg daily) and clopidogrel used,
rather than ticagrelor or prasugrel.
The evidence base for triple therapy (TT) comprising aspi-
rin, P2Y12 inhibitor (DAPT) plus oral anticoagulant (OAC)
following PCI is still evolving. In the most recent systematic
review published just prior to release of these guidelines
which analysed three prospective controlled trials and fivenon-randomised observational cohort studies comparing
OAC and single antiplatelet agents with TT (OAC and DAPT)
[164], there were no differences between the two groups in
all-cause or cardiovascular mortality, stroke, and major
bleeding, although TT was associated with significantly
lower rates of MI. However, there was considerable hetero-
geneity between studies and analysis restricted to the con-
trolled trials alone suggested a tendency towards fewer
deaths and strokes among those assigned to OAC and single
antiplatelet agents.
Given this uncertainty in the current evidence base, the
duration of triple therapy should be determined by the
bleeding risk.
 For patients with a HAS-BLED score <3, consider 3-6
months of triple therapy and then aspirin or clopidogrel
with OAC up to 12 months.
 For patients with a HAS-BLED score 3, consider 1 month
of triple therapy and then aspirin or clopidogrel with OAC
up to 12 months.
 Patients with AF at low thromboembolic risk (CHA2DS2-
VASC score =1) should be managed with dual antiplatelet
therapy for 12 months, beyond which OAC may be
considered.
 Routine concurrent use of a proton pump inhibitor should
be considered for the duration of triple therapy.
5.2.3. Glycoprotein IIb/IIIa Inhibition
Recommendation: Intravenous glycoprotein IIb/IIIa inhi-
bition in combination with heparin is recommended at the
time of PCI among patients with high-risk clinical and
angiographic characteristics, or for treating thrombotic
complications among patients with ACS. (NHMRC Level
of Evidence (LOE): IB; GRADE strength of recommenda-
tion: Strong).
Rationale: The glycoprotein IIb/IIIa inhibitors are either
recombinant antibody (abciximab) or small molecule (tir-
ofiban and eptifibatide) antagonists of platelet aggregation.
Studies of intravenous (IV) glycoprotein IIb/IIIa inhibition
in combination with heparin among ACS patients under-
going either invasive or conservative management were
conducted in an era prior to the routine use of P2Y12
inhibition. A meta-analysis of glycoprotein IIb/IIIa inhibi-
tion in ACS demonstrated a relative reduction in death or
MI (OR 0.77, 95% CI 0.65–0.92) among patients undergoing
PCI, but with an increase in major bleeding (OR 1.41, 95% CI
1.03-1.93) [165]. Collectively, these studies demonstrated
reduced rates of death or recurrent MI, moreso among those
with elevated biomarkers and undergoing PCI [166]. Two
studies examined abciximab or tirofiban upstream among
patients planned for primary PCI for STEMI, and showed
marginal benefits [167] [168]. A study of abciximab among
patients already treated with aspirin and clopiodgrel dem-
onstrated benefit in those with troponin elevation [169].
While sub-group analyses have observed similar efficacy
for prasugrel and ticagrelor over clopidogrel, regardless
of concurrent use of glycoprotein IIb/IIIa inhibitors,
930 D.P. Chew et al.studies that compare the combination of glycoprotein
IIa/IIIa and P2Y12 inhibitors with either alone have not
been conducted.
Benefits and harms: Using IV glycoprotein IIb/IIIa inhibition
among ACS patients undergoing PCI is expected to reduce
the 30-day absolute rate of death, recurrent MI by 2.6%
(NNTB 38) but increase absolute rate of major bleeding
events by 1.3% (NNTH 74). However, these estimates may
overstate reduction in ischaemic risk in association with
substantial uncertainty around bleeding risk due to the prac-
tice of upstream use in past clinical trials and lack of data
pertaining to contemporary practice. These agents should be
reserved for patients with high ischaemic risk or with throm-
botic complications during PCI.
Resources and other considerations: The incremental cost-
effectiveness of routine use of glycoprotein IIb/IIIa inhibitors
within contemporary practice has not been evaluated.
Practice advice
5.2.3.1. Timing of Glycoprotein IIb/IIIa Inhibition Initia-
tion. Compared to use during PCI, early ‘upstream’ initiation
at the time of diagnosis (i.e. prior to the cath-lab) is associated
with increased bleeding events without significant reduction
in ischaemic events. Upstream initiation may be of benefit
among patients with ongoing ischaemia, especially if there is
anticipated delay in obtaining angiography.
5.2.3.2. Glycoprotein IIb/IIIa Inhibition in Patients with
CKD. Dose adjustment of eptifibatide is recommended in
patients with CKD stage 3, and is not recommended in CKD
stage 4 and 5. Adjustment of tirofiban infusion (but not the
bolus) is required in CKD stage 4 and this agent is not
recommended in stage 5. No dose adjustment of abcixmab
is required in CKD stage 3-5, but individual bleeding risk
needs careful consideration.
5.2.3.3. Thrombocytopaenia and High Bleeding Risk.
Glycoprotein IIb/IIIa inhibition is not recommended in
patients with thrombocytopaenia (platelet count <100,000/
mL) and should be suspended immediately if platelet count
falls below this level or drops by 50% or more from baseline
on monitoring of platelet counts. Platelet transfusions should
only be considered for active bleeding. Intravenous glyco-
protein IIb/IIIa inhibition should not be used among patients
with active bleeding or receiving oral anticoagulants.
5.3. Anticoagulant Therapy
5.3.1. Heparin and Enoxaparin
Recommendation: Either enoxaparin or unfractionated
heparin (UFH) is recommended in patients with ACS at
intermediate to high risk of ischaemic events. (NHMRC
Level of Evidence (LOE): IA; GRADE strength of recom-
mendation: Strong).
Rationale: UFH is an indirect thrombin inhibitor while
enoxaparin is a low molecular weight heparin that princi-
pally inhibits factor Xa.Enoxaparin or UFH Versus Placebo: Early studies demon-
strated the benefit of UFH among ACS patients treated with
aspirin but with a rebound in ischaemic events following its
cessation. Subsequently, prolonged enoxaparin (five days)
was shown to be superior to UFH (two days) for preventing
death or recurrent MI among conservatively managed
patients. Meta-analysis of trials of NSTEACS patients largely
managed conservatively suggests that low molecular weight
heparin (LMWH) or UFH reduces recurrent MI (OR 0.40, 95%
CI 0.25-0.63), and death or MI (OR 0.61, 95% CI 0.47-0.82),
without a significant reduction in mortality. Major and minor
bleeding were increased (RR 2.05, 95% CI 0.91-4.60 and RR
6.80, 95% CI 1.23-37.49 respectively).[170].
Enoxaparin Versus UFH: Enoxaparin versus UFH in pri-
mary PCI was not associated with a reduction in death or MI
in a randomised comparison of 910 patients. However, a
meta-analysis including both randomised studies and obser-
vational studies comparing enoxaparin versus UFH across
the spectrum of patients undergoing PCI (i.e. primary PCI for
STEMI, urgent PCI and elective PCI) has reported a relative
reduction in mortality associated with enoxaparin (RR 0.66
[95% CI 0.57-0.76]) with this effect seen when used with
primary PCI for STEMI [171]. This meta-analysis reported
lower major bleeding event rates with enoxaparin. Among
fibrinolytic-treated STEMI patients, prolonged enoxaparin
(eight days) has also been shown to be superior to UFH
(two days) for the prevention of death or recurrent MI.
Benefits and harms: In conservatively managed patients,
enoxaparin or UFH reduces absolute rates of death or MI
at 30 days by 4.3% (NNTB 23) but with a 1.5% absolute
increase in major bleeding events (NNTH 65). Among
patients managed with an invasive strategy, enoxaparin
reduces absolute rates of death or MI within 30 days by
4.0% (NNTB 25) with a 1% absolute increase in major bleeding
events when compared with no therapy (NNTH 105).
Practice advice
5.3.1.1. Choice Between Indirect Thrombin Inhibitors.
Enoxaparin may be preferred over UFH as it does not require
activated partial thromboplastin time (aPTT) monitoring and
is simpler to administer. Swapping between enoxaparin and
UFH has been shown to increase bleeding risk and is not
recommended.
5.3.1.2. Standard Dosing. Among NSTEACS and STEMI
patients not receiving fibrinolyisis, the standard recom-
mended dose of enoxaparin is 1 mg/kg subcutaneous (SC)
BD. Among these patients, the recommended dosing of UFH
is 60–70 units/kg IV (max 4000 units) and initial infusion 12–
15 units/kg/hr (max 800 units/h) with target aPTT 1.5–2.5 x
control.
5.3.1.3. Patients Receiving Fibrinolysis for STEMI.
Enoxaparin with a 30 mg IV bolus (<75 years) and then
1 mg/kg SC BD is recommended in fibrinolytic-treated
patients. For those 75 years of age the dose should be
0.75 mg/kg SC BD with no IV bolus. See dose reduction in
CKD (5.3.1.5) [28,129].
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ing to PCI, those receiving UFH should receive an additional
bolus (70–100 IU/kg or 50–70 IU/kg if concomitant glyco-
protein IIb/IIIa inhibition IV) prior to the procedure. Dosing
should consider the use of UFH prior to the procedure and
guidance by activated clotting time (ACT) monitoring is
advised. Patients receiving enoxaparin do not require addi-
tional dosing if the last dose was <8 hours prior to the
procedure. For doses given 8–12 hours or >12 hours prior,
an additional bolus of 0.3 mg/kg and 0.5–0.75 mg/kg IV
respectively is recommended. For patients undergoing pri-
mary PCI, the enoxaparin dose of 0.5 mg/kg IV bolus has
been studied in a small randomised comparison and was not
superior to heparin. Crossing over between these agents (i.e.
using enoxaparin during PCI among patients with prior UFH
use or using UFH during PCI in patients treated with enox-
aparin) is not recommended. UFH or enoxaparin post-PCI is
not required in patients with successful revascularisation
and no other indication for anticoagulation.
5.3.1.5. Enoxaparin in Patients With CKD. Enoxaparin
should be dosed as 1 mg/kg daily in patients with CKD
stage 4, and is not recommended in CKD stage 5. No dose
reduction of UFH is required.
5.3.1.6. Enoxaparin or UFH in Patients Already Receiving
Warfarin or NOACs
 Patients undergoing angiography: In patients receiving
warfarin with an INR value >2.5, do not administer
intra-procedural UFH or enoxaparin prior to angiography.
 Patients undergoing PCI: The safety of PCI in patients
receiving NOACs without additional parenteral anticoa-
gulation is unknown. In intermediate risk patients at low
stroke risk receiving NOACs (AF with CHA2DS2VASC-
score <4) these agents, given their relatively short half-life,
may be suspended 24 hours prior to the procedure and
standard intra-procedural anticoagulation initiated (refer
to Section 5.3.1.2). Alternatively, additional low-dose enox-
aparin (0.5 mg/kg) or UFH (60 units/kg), regardless of the
last timing of administration of NOAC, can be considered.
Ideally, oral anticoagulants should not be ceased in
patients with atrial fibrillation and high CHA2DS2VASC-
score (>4), mechanical heart valves, or recurrent venous
thromboembolism.
5.3.2. Intravenous Direct Thrombin
Inhibition
Recommendation: Bivalirudin (0.75 mg/kg IV with
1.75 mg/kg/hr infusion) may be considered as an alternative
to glycoprotein IIb/IIIa inhibition and heparin among
patients with ACS undergoing PCI with clinical features
associated with an increased risk of bleeding events.
(NHMRC Level of Evidence (LOE): IIB; GRADE strength
of recommendation: Weak).
Rationale: The direct thrombin inhibitors antagonise the
actions of thrombin independent of antithrombin. In the
context of primary PCI for STEMI, bolus and infusion ofbivalirudin has been compared to UFH (with various rates
of glycoprotein IIb/IIIa inhibitor use) in four moderate sized
RCTs, totalling 10,000 patients [172–175]. Overall bivalir-
udin reduced bleeding events but was associated with an
increase in very early stent thrombosis, although overall
ischaemic event rates were similar. Of these, a recent single
centre trial with a high rate of radial access showed an
increase in both ischaemic and bleeding event rates with
bivalirudin as compared to UFH [175], although infusion
of bivalirudin was ceased at the end of the PCI procedure
rather than continued for two hours or more post-PCI which
is currently recommended.
Collectively, meta-analysis of clinical trials of NSTEACS
patients indicate bivalirudin is associated with a relative
reduction in bleeding events (RR 053, 95% CI 047–061)
but a trend towards increased ischaemic events, in particular
stent thrombosis compared with heparin and glycoprotein
IIb/IIIa inhibition [176]. Reductions in bleeding events are
not apparent when compared with UFH or enoxaparin alone.
A small increase in risk of early stent thrombosis has also
been consistently observed. No adequately powered studies
have compared bivalirudin with contemporary doses of UFH
or enoxaparin (i.e. without glycoprotein IIb/IIIa inhibition)
or among patients treated with prasugrel or ticagrelor.
Benefits and harms: Use of bivalirudin in ACS patients
undergoing PCI is expected to reduce absolute in-hospital
major bleeding event rates by 0.7% (NNTB 152) compared
with heparin and glycoprotein IIb/IIIa inhibition. Greater
reductions in bleeding events are likely among patients at
high bleeding risk (i.e. advanced age, female gender, low
body weight (<60 kg), anaemia, renal impairment, large cali-
bre femoral access, thrombocytopaenia, known history of
bleeding, use of multiple concurrent antithrombotic
therapies).
Resources and other considerations: The cost-effectiveness of
bivalirudin versus UFH has not been studied.
Practice advice
5.3.2.1. Dose Reduction in CKD. In CKD stage 4 and stage 5,
no reduction in the bolus dose is required but infusions
should be reduced to 1.0 mg/kg/hr and 0.25 mg/kg/hr,
respectively.
5.3.2.2. Risk Assessment. In the context of routine assess-
ment of ischaemic and bleeding risk, as well as the risk of
stent thrombosis, bivalirudin may be preferred among
patients undergoing PCI with low risk of ischaemic events
and high bleeding risk.
5.4. Duration of Cardiac Monitoring
No studies have prospectively evaluated the optimal dura-
tion of monitoring among patients with suspected or con-
firmed ACS. Clinical assessment for the risk of life-
threatening arrhythmia should be individualised based on
factors known to be associated with increased risk (e.g.
clinically significant arrhythmias, ongoing discomfort, failed
reperfusion, haemodynamic compromise, LV ejection
932 D.P. Chew et al.fraction <40%, known stenoses of major coronary vessels,
complications of PCI [side branch occlusion or distal embo-
lisation]). The following practice advice based on the clinical
status of the patient is suggested.
Practice advice
5.4.1.1 Patients with suspected ACS and unstable angina in
whom symptoms have resolved, initial ECGs shows no
ischaemic changes (including the absence of LBBB), and
initial troponin value is within normal reference range donot require continuous ECG monitoring. Recurrent symp-
toms should prompt re-evaluation (refer to Section 2.5.1.6).
5.4.1.2 Patients with MI at low risk of arrhythmias (i.e.
absence of risk characteristics described above) should be
monitored for 24 hours or until successful revascularisation
has occurred (whichever comes later).
5.4.1.3 Patients with characteristics associated with an
increased risk of arrhythmias (e.g, QT prolongation (includ-
ing drug-related) and prior ventricular arrhythmias) should
be monitored for >24 hours.
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Secondary Prevention
Secondary prevention strategies are critically important for
reducing the occurrence of new vascular events in patients
surviving to discharge from hospital with a confirmed diag-
nosis of ACS. These strategies comprise the adoption by
patients of healthy behaviours (e.g. quitting smoking, being
physically active, eating healthily), intensive risk factor mod-
ification (e.g. controlling hypertension, managing diabetes
mellitus) and adherence to proven cardioprotective medica-
tions (e.g. aspirin, another antiplatelet drug, statin, beta-
blockers, angiotensin co-enzyme inhibitors/angiotensin
receptor blockers). In addition, strategies to avoid the pre-
cipitants of ACS (medications and vaccinations) should be
considered. Finally, referral to secondary prevention or reha-
bilitation services and the provision of a chest pain manage-
ment plan are important in providing comprehensive care
among patients recovering from an ACS event and transi-
tioning to the chronic self-management of CAD.
6.1. Late and Post-Hospital
Pharmacotherapy
6.1.1. Long-term Antiplatelet Therapy:
Refer to section 5.2.1 and 5.2.2
Recommendations:
(a) Aspirin (100–150 mg/day) should be continued indefi-
nitely unless it is not tolerated or an indication for
anticoagulation becomes apparent. (NHMRC LOE IA,
GRADE strength of recommendation: Strong).
(b) Clopidogrel should be prescribed if aspirin is contra-
indicated or not tolerated. (NHMRC LOE IA, GRADE
strength of recommendation: Strong).
(c) Dual-antiplatelet therapy with aspirin and a P2Y12
inhibitor (clopidogrel, or ticagrelor) should be pre-
scribed for up to 12 months in patients with ACS,
regardless of whether coronary revascularisation was
performed. The use of prasugrel for up to 12 months
should be confined to patients receiving PCI. (NHMRC
LOE IA, GRADE strength of recommendation: Strong).
(d) Consider continuation of dual-antiplatelet therapy
beyond 12 months if ischaemic risks outweighs the
bleeding risk of P2Y12 inhibitor therapy; conversely
consider discontinuation if bleeding risk outweighs
ischaemic risks. (NHMRC LOE IIC, GRADE strength
of recommendation: Weak).
Practice advice
6.1.1.1 Extending P2Y12 inhibition up to 3 years with either
clopidogrel or ticagrelor may be considered in patients at
high risk of recurrent ischaemic events (e.g. particularly
those receiving coronary stents or suffering ischaemic events
while on aspirin) with low bleeding risk.
6.1.1.2 Consider using appropriate objective measures or risk
scoring to assist in weighing future ischaemic risk and bleed-
ing risk, as described in Section 3.2.6.1.2. Statins
Recommendation: Initiate and continue indefinitely, the
highest tolerated dose of HMG-CoA reductase inhibitors
(Statins) for a patient following hospitalisation with ACS
unless contraindicated or there is a history of intolerance.
(NHMRC LOE IA, GRADE strength of recommendation:
Strong).
Rationale: Statin therapy is effective in reducing low-den-
sity lipoprotein-cholesterol (LDL-C), reduces arterial inflam-
mation, stabilises the lipid core, and helps to regress
atherosclerotic plaque. Long-term statin therapy lowers the
annual risk of major vascular event by about 20% for every
1mmol/L reduction in LDL cholesterol [177]. A meta-analy-
sis of individual participant data from 22 trials of statin
therapy versus controls (n=134,537) and five trials of high
versus lower dose statins (n=39,612) reported the relative
reduction in non-fatal MI, ischaemic stroke, and all-cause
death per 1.0 mmol/L reduction in LDL as: 0.74 (95% CI 0.71-
0.77), 0.79 (95% CI 0.74-0.85) and 0.91 (95% CI 0.88-0.93),
respectively. In the subset of people with pre-existing vascu-
lar disease (n=64,443) the composite endpoint of MI, stroke,
coronary revascularisation or vascular death was reduced by
20% for every 1.0 mmol/L reduction in LDL (RR 0.80 [95% CI
0.77-0.82]). Another meta-analysis of eight studies involving
13,208 patients with ACS found initiation of statin therapy
before or after PCI led to 35 fewer MACE at 12 months per
1,000 treated [178]. Of note, many of the trials cited predated
contemporary coronary revascularisation. High-dose statins
versus no- or low-dose statins reduced the combined end-
point of death, recurrent MI and stroke (OR 0.52, 95% CI 0.37-
0.73). There was non-significant reduction in MI (OR 0.81,
95% CI 0.65-1.01; P = 0.06). The benefit of fewer deaths, MI
and strokes occurs within the first 6 months after ACS.
Benefits and harms: Statins are estimated to reduce the abso-
lute 2-year vascular event rate by at least 1.1% (NNTB 93) in
patients with established CAD. There is no evidence that
reduction of LDL cholesterol with a statin increases cancer
incidence, cancer mortality, or other non-vascular mortality.
Resources and other considerations: Referral to an accredited
practising dietitian to assist with following a healthy eating
pattern to improve blood cholesterol levels should be
considered.
Practice advice
6.1.2.1. Timing of Initiation. Initiate statin therapy early
during the ACS admission, irrespective of baseline LDL-C
level. Lower intensity statin therapy should be used for those
at greater risk of side effects such as myositis on the basis of
otherwise unexplained chronically elevated creatine kinase
levels. Recheck total and LDL cholesterol level (at approxi-
mately 3 months) and adjust statin therapy according to
whether levels are at target values.
6.1.2.2. Target Cholesterol Levels. There is additional bene-
fit from progressive lowering of cholesterol levels with no
apparent lower limit. Within the context of an individualised
care plan, a target LDL cholesterol level 1.8 mmol/L is
suggested in the first instance.
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firmed ACS event represents an opportunity for lifestyle
counselling aimed at the patient’s family, events among
younger patients (i.e. <50 years of age in males and <60 years
of age in females) warrant the consideration of genetic pre-
disposing factors such as familial hypercholesterolaemia,
which, if confirmed on cascade screening, may lead to initia-
tion of statins among family members.
6.1.2.4. Statin Intolerance. Given the substantial evidence
base demonstrating the benefits of statins among patients
with ACS, reported statin intolerance should be carefully
reexamined. Some patients (up to 70%) reporting statin intol-
erance may tolerate reduced dose regimens or more hydro-
philic agents [179].
6.1.2.5. Sub-optimal LDL. Among patients with suboptimal
LDL cholesterol levels or who are statin intolerant, ezetimibe
10 mg daily should be considered [180].
6.1.3. Beta-blockers
Recommendation: Initiate treatment with vasodilatory
beta-blockers in patients with reduced LV systolic function
(LV ejection fraction [EF] 40%) unless contraindicated.
(NHMRC LOE IIA, GRADE strength of recommendation:
Strong).
Rationale: The evidence supporting use of beta-blockers is
stronger among patients with reduced LV function following
ACS. Importantly, the vasodilatory beta-blockers (e.g. carve-
dilol, bisoprolol, nebivolol and metoprolol succinate) reduce
peripheral vascular resistance while maintaining or improv-
ing cardiac output, stroke volume and left ventricular func-
tion. They may also limit infarct size [181,182]. Beta-blocker
therapy appears to reduce mortality in patients after MI [183–
185], although many of the relevant trials predate current
reperfusion, revascularisation, dual antiplatelet and statin
practice [181,182]. A meta-analysis of 31 long-term (6-48
months) trials randomising 24,184 patients post MI to either
beta-blockers or placebo, in addition to background aspirin
and lipid-lowering therapy, found a 23% reduction in all-
cause mortality, but no reduction in recurrent MI. When the
results were stratified according to use of reperfusion or
revascularisation, the benefit of beta-blockers was dimin-
ished [185] (Refer to section 5.1.1.3). However, evidence of
benefit for vasodilatory beta-blockers was stronger among
patients with reduced LV function following ACS. The qual-
ity of past evidence for routine beta-blocker use was strong
but is no longer applicable to current practice.
Benefits and harms: With long-term care, beta-blocker ther-
apy is estimated, on the basis of only moderate quality evi-
dence, to lower the risk of death by 23% [186], with a NNTB
of 42 for 2 years to avoid one death among patients with
reduced LV function. Within current practice, the incremen-
tal benefit of beta-blockers is not well established and likely
to be marginal among patients with successful revascular-
isation, preserved LV function, no ongoing angina or resid-
ual ischaemia. The adverse effects of beta-blocker therapyinclude bradycardia, hypotension, bronchospasm, fatigue,
reduced libido, depression, new onset diabetes and the addi-
tional medication burden.
Practice advice
6.1.3.1 The applicability of trial evidence for long-term post
MI beta-blocker therapy within contemporary practice is
unclear given the widespread use of reperfusion and throm-
bolytic therapy, statins and renin-angiotensin-aldosterone
system antagonists. Most of the data suggests a reduction
in total mortality, re-infarction and sudden cardiac death in
the first 3 years of beta-blocker use, particularly in patients
with LV systolic dysfunction. Most of the benefit occurs
within the first year of acute MI, with benefit beyond one
year being less evident. Overall, low-risk asymptomatic
patients or those with preserved LV ejection fraction benefit
the least from beta-blocker therapy which could be ceased at
12 months. Beta-blockers continue to have a role in the
medical management of stable angina.
6.1.4. Renin-angiotensin Antagonists
Recommendation: Initiate and continue angiotensin con-
verting enzyme (ACE) inhibitors (or angiotensin receptor
blockers [ARBs]) in patients with evidence of heart failure,
LV systolic dysfunction, diabetes, anterior MI or co-exis-
tent hypertension. (NHMRC LOE IA, GRADE strength of
recommendation: Strong).
Rationale: The purpose of renin-angiotensin antagonists
post ACS is for cardioprotection. Survival following MI with
or without evidence of LV systolic dysfunction or heart
failure is improved by the use of ACE inhibitors [187,188],
attributed to their ability to limit infarct size and reduce
ventricular remodeling. The combined findings of three large
trials [188] showed long-term use of ACE inhibitors signifi-
cantly reduced all-cause mortality (7.8 vs 8.9%, p=0.0004),
cardiovascular mortality (4.3 vs 5.2%, p=0.0002), non-fatal MI
(5.3 vs 6.4%, p=0.0001), stroke (2.2 vs 2.8%, p=0.0004), heart
failure (2.1 vs 2.7%, p=0.0007) and composite of cardiovascu-
lar mortality, non-fatal MI, or stroke (10.7% vs 12.8%,
p<0.0001). Overall, ACE-inhibition is associated with
a reduction in cardiovascular mortality (OR 0.82; 95%
CI 0.76–0.88; p<0.0001), non-fatal MI and stroke in the con-
text of long-term secondary prevention.
Benefits and harms: Benefits of ACE inhibitors were noted in
patients taking beta-blockers, lipid-lowering agents, and
antiplatelet therapy, individually or together. ACE-inhibi-
tion is expected to reduce absolute rates of major vascular
events by 2.1% (NNTB 48) over 4-5 years, though this benefit
is less striking among those patients with none of the listed
concurrent indications. Adverse effects associated with ACE
inhibitors include falls, dizziness, hypotension, hyperkalae-
mia, fatigue, acute kidney injury, cough and angio-oedema.
Practice advice
6.1.4.1. ACE-I vs ARB. An angiotensin receptor blocker
(ARB) is an alternative to ACE inhibitors in those intolerant
to such treatment, with evidence suggesting similar levels of
benefit in patients with ACS and no heart failure.
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renin-angiotensin antagonism post ACS is cardiac protection.
For patients with concurrent hypertension, ACE inhibitors
and ARBs are indicated as first-line agents and current blood-
pressure management and targets are provided in the Heart
Foundation hypertension guidelines [189].
6.2. Secondary Prevention
6.2.1. Establishing a Secondary
Prevention Plan and Referral to Cardiac
Rehabilitation
Recommendation: Attendance at cardiac rehabilitation or
undertaking a structured secondary prevention service is rec-
ommended for all patients hospitalised with ACS. (NHMRC
LOE IA, GRADE strength of recommendation: Strong).
Rationale: A key component of establishing effective sec-
ondary prevention services within individuals with ACS is
teaching self-management of chronic CAD, adopting healthy
behaviours including regular exercise, controlling biomedi-
cal indices and adhering to cardioprotective medicines [190].
Light-to-moderate exercise (increased breathing while able to
sustain a conversation) is preferred to vigorous exercise (e.g.
puff and pant and unable to sustain a conversation), which
has been known to trigger a cardiovascular event, particu-
larly in people who are habitually sedentary. Among indi-
viduals with established CAD, the estimated rates for non-
fatal and fatal cardiovascular events are 1 per 115,000 patient-
hours and 1 per 750,000 patient hours of supervised exercise
respectively [191]. Exercise-induced cardiac events are neg-
ligible in comparison to the day-to-day risk associated with
being sedentary. Communication practices around the time
of patient discharge, and during attendance to cardiac reha-
bilitation represents distinct critical times for imparting the
necessary information for patients to acquire the capacity for
both self-care and life-long prevention.
Earlier systematic reviews of all RCTs comparing usual
medical care to either cardiac rehabilitation or structured
secondary prevention in people with CAD favoured the inter-
vention group for all-cause mortality at 1 and 3 years, partic-
ularly in those post-MI. The recent systematic review of 63
studies randomising 14,486 patients to either exercise-based
cardiac rehabilitation or usual care with a median follow-up
of 12 months showed falls in cardiovascular mortality and
hospital admissions (RRs 0.74, 95% CI 0.64-0.86 and 0.82, 95%
CI 0.70-0.96 respectively) [192]. There was no significant effect
on all-cause mortality (RR 0.96, 95% CI 0.88-1.04), MI (RR 0.90,
0.79-1.04), PCI (RR 0.85, 95% CI 0.70-1.04) and CABG (RR 0.96,
95% CI 0.80-1.16). These benefits appeared to be consistent
across patient categories (including those at-risk) and inter-
vention types (comprehensive and exercise only) and inde-
pendent of setting (centre-based, home or combined) and
publication date (pre-1995, post-1995). An earlier meta-anal-
ysis of 63 randomised trials (n=21,295 patients with coronary
disease) encompassing a variety of secondary prevention
formats, components and settings reported a risk ratio of
0.85 (95% CI 0.77-0.94) for all-cause mortality over 24 months[193]. These findings included ACS patients who were
stented, surgically revascularised or treated medically.
Benefits and harms:Among patients who attend and com-
plete a secondary prevention program, the absolute risk of
cardiovascular death, MI and stroke at 12 months is reduced
by approximately 4.5% (NNTB 22) in patients recovering
from ACS [192].
Resources and other considerations: Large metropolitan
centres who care for significant numbers of ACS patients
and are appropriately staffed and resourced will likely provide
combinations of comprehensive facility and home-based car-
diac rehabilitation programs for both individuals and groups.
However, many ACS survivors may prefer home-based, indi-
vidualised coaching services mediated by telephone or pro-
grams offered in community or primary-care settings, all of
which are more convenient and accessible [194]. These various
formats can be supplemented with multimedia educational
resources such as manuals, DVDs and text message [190,195–
198]. Contemporary cost-effectiveness analyses of different
approaches to counseling and cardiac rehabilitation/second-
ary prevention services for patients after ACS are required.
Practice advice
6.2.1.1. Discharge Processes. While robust evidence sup-
porting the implementation of specific local practices at the
time of discharge are not available, the format and content
of secondary prevention and self-care instruction is likely to
be important. Furthermore, ensuring the provision of advice
in a culturally and linguistically appropriate manner, with
particular consideration among Aboriginal and Torres Strait
Islander patients and CALD groups, is likely to be an impor-
tant aspect of communication. A comprehensive, individual-
ised and consistently delivered process for ensuring ACS
patients receive the required secondary prevention informa-
tion at the time of discharge is recommended.
Components of advice: During the ACS admission and,
where appropriate, initiate lifestyle counselling on smoking
cessation, ambulatory exercise and healthy eating. This
advice should be clearly documented in the discharge com-
munication to the patient, their companion(s) and all treating
health professionals.
Chest pain management plan: Prior to discharge with a diag-
nosis of ACS, patients should receive an angina symptom
management plan which entails guidance on the use of pre-
scribed medicines to manage acute worsening or new unsta-
ble angina symptoms, and when and how (i.e. call ambulance
rather than self-drive) to present to EDs for acute care. A copy
of their latest ECG should also be provided to the patient.
6.2.1.2. Individualisation of Cardiac Rehabilitation/sec-
ondary Prevention Service Referral. A wide variety of pre-
vention programs improve health outcomes in patients with
coronary disease. Following discharge from hospital patients
with ACS and where appropriate their companion(s) should
be referred to an individualised preventive intervention
according to personal preference, values and the available
resources. Services can be hospital-based, in primary care,
the local community or in the home.
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Measures of Performance and
Clinical Standards
Audits in Australia suggest unexplained variations in the
management of ACS patients which do not accord with
contemporary guideline recommendations. The intensity
of care that patients receive is often inversely related to their
underlying disease risk (and hence likelihood of benefit)
[117], and patients with certain co-morbidities are less likely
to receive evidence-based care despite the absence of contra-
indications [199]. Adherence to ACS guidelines has been
correlated with improvements in patient outcomes, includ-
ing reduced mortality. Furthermore, an ACS Clinical Care
Standards and accompanying indicator specification have
recently been developed by the Australian Commission for
Safety and Quality in Health Care (ACSQHC) [1]. This stan-
dard focusses on aspects of chest pain and ACS care more
frequently associated with unwarranted variation, and
which potentially have the greatest impact on patient out-
comes. Mechanisms enabling health services in the collection
of some of this data, including the National Quality Use of
Medicines Indicators, have been developed and validated. It
is recognised that consistently providing care as described in
the Clinical Care Standard and ensuring guideline-concor-
dant care will require the development of local protocols and
pathways, combined with specific health service design char-
acteristics that ensure consistent and timely access to indi-
vidualised diagnostic expertise and therapeutic
interventions. (Refer to ‘‘Resource and other considerations’’
in Sections 2.1.3, 2.4.1.3, 3.2.1, 4.1.2.3, 4.2.1.2, and 6.2.1).
Continuous audit and feedback systems, integrated with
work routines and patient flows, are strongly advocated to
support quality assurance initiatives and provide data con-
firming continued, cost-efficient improvement in patientoutcomes as a result of new innovations in care. Potentially
useful quality and outcome indicators for patients presenting
with suspected and confirmed ACS include:
1. Time from presentation to first ECG in patients present-
ing with suspected ACS;
2. Proportion and appropriate identification of suspected
ACS patients managed under a Suspected ACS-AP;
3. Rate of 30-day death and MI among patients managed
under a Suspected ACS-AP;
4. Door-to-device time among patients with STEMI under-
going primary PCI;
5. Door-to-needle time among patients with STEMI under-
going fibrinolysis;
6. Proportion of high-risk NSTEACS patients in whom the
options for invasive management versus conservative
management have been discussed;
7. Proportion of ACS patients who receive a prescription of
aspirin and a P2Y12 inhibitor at the time of discharge;
8. Proportion of ACS patients who receive a prescription of
a statin at the time of discharge;
9. Proportion of ACS patients who receive a prescription of
an ACE-inhibitor or ARB at the time of discharge;
10. Proportion of ACS patients who receive personalised
lifestyle (diet, exercise, cessation of smoking) advice at
the time of discharge;
11. Proportion of ACS patients who receive a personalised
chest pain action plan;
12. Proportion of ACS patients who receive a referral to a
cardiac rehabilitation or secondary prevention program;
13. The 30-day mortality rate among patients with con-
firmed ACS;
14. The 30-day rate of new or recurrent MI among patients
with confirmed ACS;
15. The 12-month mortality rate among patients with con-
firmed ACS.
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 Randomised comparisons of very short (0 and 1 hour) ACS
rule-out pathways using high-sensitivity troponin assays
compared with standard care.
 The role of other biomarkers in patients with possible AMI,
including heart-type fatty acid-binding protein (hFABP)
and copeptin, where sensitive and highly sensitive tropo-
nin assays are available.
 Defining patients who do not need further objective testing
for symptomatic ischaemia or anatomically significant
CAD.
 Appropriate length of stay for MI. The efficacy in terms of bleeding events and ischaemic
events of single antiplatelet therapy with newer P2Y12
inhibitors, compared with dual antiplatelet therapy fol-
lowing ACS.
 Optimal combinations of antiplatelet therapies and long-
term anticoagulation for patients at various degrees of risk
for recurrent ischaemic and bleeding events.
 The cost-effectiveness of current and emerging approaches
to secondary prevention programs.
 The fidelity of specific performance measures in chest pain
assessment and ACS care and their correlation with late
clinical and patient reported outcomes.
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Approved in Australia
9.1. Rivaroxaban
Rivaroxaban, an oral factor Xa inhibitor is approved (15 mg
or 20 mg orally daily) for use among patients with non-
valvular atrial fibrillation. Among patients with ACS without
known atrial fibrillation, 2.5 mg and 5 mg twice daily dosing
has been studied in addition to dual antiplatelet therapy for a
duration of 13–31 months. Both doses were associated with
reductions in cardiovascular death, recurrent MI and stroke,
with the 2.5 mg dose reducing cardiovascular mortality
(2.7% vs 4.1%, p=0.002) and all-cause mortality (2.9% vs
4.5%, p=0.002). However, rivaroxaban increased the rate of
non-CABG related major bleeding (2.1% vs 0.6%, P<0.001)
and intracerebral haemorrhage (0.6% vs 0.2%, P=0.009). Use
of rivaroxaban in these doses in addition to dual anti platelet
therapy will require careful clinical assessment of ischaemic
and bleeding risk. This agent is not currently approved for
use for this indication and at these doses in Australia.
9.2. Cangrelor
Cangrelor is an intravenous agent with immediate onset,
short-acting (duration 1–2 hours) reversible P2Y12 inhibitor
which has been shown in meta-analysis of several PCI trials
involving patients with ACS to reduce periprocedural MI
with only modest increase in bleeding events, particularly
among patients not initially loaded with clopidogrel (note: in
STEMI, absorption of the oral P2Y12 inhibitors is slowed and
platelet inhibition may be delayed by several hours). Com-
pared with clopidogrel initiated at the time of PCI, cangrelor
is associated with a relative reduction in death, recurrent MI,
urgent revascularisation and stent thrombosis by 48 hours of
13% (OR 0.87, 95% CI 0.78-0.99, p=0.007), and a relativeincrease in major bleeding of 38% (OR 1.38 95% CI 1.03-
1.85, p=0.029). This agent may have a role as a periprocedural
antiplatelet therapy in patients not adequately loaded with
oral P2Y12 inhibition.
9.3. Fondaparinux
Fondaparinux is a synthetic pentasaccharide parenteral
selective factor Xa inhibitor that binds reversibly and non-
covalently to antithrombin with high affinity, thereby pre-
venting thrombin generation. In NSTEACS, the recom-
mended dose is 2.5 mg daily subcutaneously. Large-scale
clinical trials have demonstrated non-inferiority of this agent
when compared with enoxaparin, with substantial benefits in
terms of reduced bleeding events. However, when used
among patients undergoing early invasive management,
supplemental heparin is required to prevent catheter throm-
bosis. This agent is not currently approved for use in
Australia for patients with ACS and no future application
is anticipated. Therefore, no formal recommendation regard-
ing the use of this agent is provided.
9.4. Vorapaxar
Vorapaxar is an orally active PAR-1 inhibitor of the thrombin
receptor activating peptide (TRAP), thereby inhibiting plate-
let aggregation. A secondary prevention study of 26,449
patients with MI, stroke and peripheral vascular disease,
randomisation to vorapaxar was associated with a lower rate
of cardiovascular death, MI and stroke over three years
(vorapaxar 9.3% vs placebo 10.5%, HR 0.87; 95% CI 0.80-
0.94, p<0.001). However clinically significant bleeding
events, including intracerebral haemorrhage, occurred with
greater frequency than the reduction in ischaemic events
(vorapaxar 15.8% vs. placebo 11.1%, HR 1.46; 95% CI 1.36-
1.57, p<0.001). This agent is not currently approved for use
in Australia.
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- Australasian College for Emergency Medicine (ACEM)
- Australian Cardiovascular Health and Rehabilitation
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Appendix 3: Clinical Questions for NHFA/CSANZ ACS Guideline
Update Literature Review
Clinical Questions for NHFA/CSANZ ACS Guideline Update Literature Review
Clinical Question: Chest Pain
1. In adult patients presenting to the Emergency Department (ED) with chest pain what evidence exists regarding clinical approaches for risk
stratification pathways/protocols (e.g. TIMI score, GRACE score, HEART score, ADAPT, modified ADAPT, ASPECT, EDACS-ADP, NHFA Risk
Stratification or MACS rule) to optimise outcomes of safety (risk for 30-day events of death, acute myocardial infarction (AMI), or
revascularisation), length of stay, and cost effectiveness not included in the current National Heart Foundation (NHF) guideline recommendations
for assessment of possible acute coronary syndrome (ACS)?
a) Secondary safety endpoint: 30-day events for arrhythmia, heart failure, and readmission
Clinical Question: Chest Pain
2. In adult patients presenting to ED with suspected ACS, what are the time- and assay-dependent performance characteristics of biomarkers in
diagnosing acute myocardial infarction (AMI)?
a) How do these performance characteristics vary according to:
i. Assay type (Troponin – I (TnI) or Troponin T (TnT)), sensitive or highly-sensitive assays, point of care or laboratory assays?
ii. Timing (on admission, 2 hours, 4 hours, 6 hours, 12 hours after admission or after symptom onset)?
Clinical Question: Chest Pain
3. In adult patients presenting to ED with suspected ACS and in whom AMI has been ruled out:
a) which subsequent test (Exercise Stress Test (EST), Stress Echocardiography (ECHO), nuclear medicine testing, CT Coronary Angiogram (CTCA),
Magnetic Resonance Imaging (MRI)) is most accurate and cost-effective in detecting symptomatic coronary ischaemia?
b) when should the test be performed (e.g. within 72 hours, within 30 days)? Are there different time frames for different risk cohorts?
c) Are there subgroups in whom further testing is unnecessary?
Clinical Question: Secondary Prevention
4. In hospitalised adults with ACS (by STEMI, NSTEMI, Unstable Angina (UA)) what is the evidence that prescription of multiple/cumulative
cardio-protective medicines (including: aspirin, other antiplatelet agent, statin, beta-blocker, angiotensin converting enzyme inhibitor/angiotensin
receptor blocker) (including order) prior to discharge from hospital compared to single or no medicines improves the composite endpoint of all-cause
and cardiac mortality, myocardial infarction and stroke by 12 months or longer?
Clinical Question: Secondary Prevention
5. In hospitalised adults with ACS (by STEMI, NSTEMI, UA) what is the evidence that documented referral to secondary prevention (e.g. post-
hospital cardiac rehabilitation), receipt of lifestyle counselling on smoking cessation, exercise, healthy eating and angina symptom management
advice compared to no referral and no counselling improves health related quality of life and the composite endpoint of all-cause mortality,
myocardial infarction and stroke at 12 months?
Clinical Question: Secondary Prevention
6. In hospitalised adults with ACS (by STEMI, NSTEMI, UA) what is the evidence that documented receipt of optimal secondary prevention
(including lifestyle counselling, referral to secondary prevention service) and cumulative (>1) cardio-protective medicines prior to discharge from
hospital compared to no counselling or referral to secondary prevention service and single or no medicines is cost-effective beyond 12 months?
Clinical Question: NSTEACS
7. In adult patients with NSTEACS, does a routine invasive approach of coronary angiography and possible revascularization in all patients confer
greater net clinical benefit (reduction in rates of major cardiac events weighed against rates of bleeding events) than an initial ischaemia guided
approach?
How does this net benefit vary according to:
1) results of biomarkers
2) clinical co-morbidities and
3) overall patient risk using current stratification tools?
Clinical Question: NSTEACS
8. Among adults with NSTEACS undergoing planned invasive management, what is the optimal timing for performing coronary angiography and
possible revascularization in order to reduce the risk of recurrent MI or death when considering patient risk characteristics and the specific time
categories below?:
- Emergent (STEMI like)
- same day (i.e. call in the laboratory if necessary/arrange urgent transfer if at a non-cath-lab hospital)
- within 24 hours (i.e. can leave overnight, but do over weekend)
- within 48 hours
- during admission.
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Clinical Question: NSTEACS
9. In adult patients with NSTEACS, which antithrombotic drug combination, including P2Y12 inhibitors, confer greatest net benefit (reduced rates of
cardiac events vs rates of bleeding events) during hospital admission and by 12 months?
a) How does this benefit vary according to patient subgroups (invasive versus conservative management, increased need for cardiac surgery or non-
cardiac surgery, age >70 years, atrial fibrillation, renal impairment [eGFR <30; <45; <60])?
Clinical Question: STEMI
10. Among patients presenting with STEMI, comparing delay to percutaneous coronary intervention (First Medical Contact* (FMC) to first device)
with delay to fibrinolysis (FMC to needle), what is the maximum acceptable time delay to percutaneous coronary intervention (PCI) after which
fibrinolysis is associated with a lower rate of 30-day or 1 year mortality, and is the ‘tolerable’ time delay different for those with onset to FMC
<120 min compared to FMC >120 min?
a) Does the rate and timing of angiography/angioplasty during the initial hospitalisation in STEMI patients, who successfully and unsuccessfully
received fibrinolytic therapy, affect this conclusion?
*First Medical Contact (FMC) includes a paramedic or nurse who can administer fibrinolysis
Clinical Question: STEMI
11. For adult patients with STEMI, what system-based strategies (e.g. protocols, clinical support networks, community education programs) have been
associated with a higher proportion of patients receiving timely reperfusion, with consideration for fibrinolysis and primary PCI collectively and
separately, and do such systems alter 30-day or 1 year mortality?
Clinical Question: STEMI
12. For adult patients with STEMI undergoing reperfusion treatments, what combination of antithrombin and antiplatelet therapies result in the best
net clinical benefit over 30-days or 1 year (i.e. lowest rate of major adverse cardiac events of death, MI, and stroke, weighed against bleeding events),
a) with primary PCI and b) with fibrinolytic therapy?
Appendix 4: NHMRC Guideline Development Methodology [13]
See Tables A1–A3.
Table A1 NHMRC level of evidence
Level Intervention Diagnostic Accuracy Prognosis Aetiology Screening
Intervention
I A systematic review of
level II
studies
A systematic review of level
II studies
A systematic review
of level II studies
A systematic review
of level II studies
A systematic review
of level II studies
II A randomised controlled
trial
A study of test accuracy with
an independent, blinded
comparison with a valid
reference standard, among
consecutive persons with a
defined clinical presentation
A prospective cohort
study
A prospective cohort
study
A randomised
controlled trial
III-1 A pseudorandomised
controlled trial
(i.e. alternate allocation or
some other method)
A study of test accuracy with
an independent, blinded
comparison with a valid
reference standard, among
non-consecutive persons with
a defined clinical presentation
All or none All or none A pseudorandomised
controlled trial
(i.e. alternate
allocation or some
other method)
III-2 A comparative study with
concurrent controls:
b Non-randomised,
experimental trial
b Cohort study
b Case-control study
b Interrupted time series
with a control group
A comparison with reference
standard that does not meet
the criteria required for
Level II and III-1 evidence
A retrospective cohort
study
A comparative study
with concurrent
controls:
b Non-randomised,
experimental trial
b Cohort study
b Case-control study
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Table A1. (Continued).
Level Intervention Diagnostic Accuracy Prognosis Aetiology Screening
Intervention
III-3 A comparative study
without concurrent
controls:
b Historical control study
b Two or more single arm
study
b Interrupted time series
without a parallel control
group
Diagnostic case-control study A retrospective cohort
study
A case-control study A comparative study
without concurrent
controls:
b Historical control
study
b Two or more single
arm study
IV Case series with either
post-test or pre-test/post-
test outcomes
Study of diagnostic yield (no
reference standard)
Case series, or cohort
study of persons at
different stages of
disease
A cross-sectional
study or case series
Case series
Table A2 NHMRC body of evidence matrix
Component A: Excellent B: Good C: Satisfactory D: Poor
Evidence One or more level I trials
with a low risk of bias or
several level II trials with
low risk of bias
One or two level II trials
with a low risk of bias or a
systematic review/several
level III trials with a low
risk of bias
One or two level III trials
with a low risk of bias or a
level I or II trials with a
moderate risk of bias
Level IV trials, or level 1 to
III trials/systematic
reviews with a high risk of
bias
Consistency All trials consistent Most trials consistent and
inconsistency may be
explained
Some inconsistency
reflecting genuine
uncertainty around clinical
question
Evidence is inconsistent
Clinical Impact Very large Substantial Moderate Slight or restricted
Generalisability Population/s in evidence
summary are the same as
the target population for
the guideline
Population/s in evidence
summary are similar to the
target population for the
guideline
Population/s in evidence
summary differ to target
population for the
guideline but is clinically
sensible to apply to target
population
Population/s in evidence
summary differ to target
population and hard to
judge whether it is sensible
to generalise to target
population
Applicability Directly applicable to
Australian heart care
Applicable to Australian
heart care context with few
caveats
Probably applicable to
Australian heart care
context with some caveats
Not applicable to
Australian heart care
context
Table A3 NHMRC grades of recommendation
Grade of Recommendation Description
A Body of evidence can be trusted to guide practice
B Body of evidence can be trusted to guide practice in most situations
C Body of evidence provides some support for recommendation/s but care should be taken in its application
D Body of evidence is weak and recommendation must be applied with caution
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Appendix 5: GRADE Methodology for Recommendations [12]
Strength of recommendation using GRADE Methodology
Strong against Weak against Weak for Strong for
Within GRADE methodology there are two strengths of recommendation: Strong or Weak/conditional. The direction and
strength of each recommendation is determined on the basis of four key factors: level of confidence in effect estimates (as
determined by quality of evidence), balance between benefits and harms, uncertainty or variability in patients’ values and
preferences, and resource considerations.
The strength of the recommendation is defined by the following principles [213]:
GRADE METHODOLOGY
Strong recommendation High or moderate confidence in effect estimates AND
Benefits clearly outweigh the harms or vice versa AND
All or almost all fully informed patients will make the same choice AND
Benefits of the intervention are clearly justified in all or almost all circumstances of resource allocation
Weak recommendation Low or very low confidence in effect estimates OR
Balance between benefits and harms is close OR
Variability or uncertainty in what fully informed patients may choose OR
Benefits of the intervention may not be justified in some circumstances of resource allocation
Abbreviations and Acronyms
ABS
ACE
ADP
ADAPT
Australian Bureau of Statistics
Angiotensin converting enzyme
Accelerated diagnostic protocol
2-Hour Accelerated Diagnostic Protocol to Assess Patients with Chest
Pain Symptoms Using Contemporary Troponins as the Only Biomarker
AIHW
ARB
CABG
CAD
Suspected ACS-AP
CSANZ
ECG
EDACS
ED
FFE
GRACE
GRADE
HR
Australian Institute of Health and Welfare
Angiotensin receptor blockers
Coronary artery bypass grafting
Coronary artery disease
Suspected acute coronary syndrome assessment protocol
Cardiac Society of Australia and New Zealand
Electrocardiogram
Emergency Department Assessment of Chest pain Score
Emergency department
Freedom from event
Global Registry of Acute Coronary Events
Grading of Recommendations Assessment, Development and Evaluation
Hazard ratios
HEART
IABP
LR
LVEF
MI
NACPR
NHFA
NNTB
NNTH
History, electrocardiogram, age, risk factors, troponin
Intra-aortic balloon pump
Likelihood ratio
Left ventricular ejection fraction
Myocardial infarction
North American Chest Pain Rule
National Heart Foundation of Australia
Number needed to benefit
Number needed to harm
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NPV
NSTEACS
OR
PCI
POC
PPV
RR
NPV
STEMI
TIMI
UA
Negative predictive values
Non-ST elevation acute coronary syndromes
Odds ratio
Percutaneous coronary intervention
Point-of-care
Positive predictive value
Relative risk
Negative predictive value
ST elevation myocardial infarction
Thrombolysis in myocardial infarction
Unstable angina
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